A mathematical model of viral oncology as an immuno-oncology instigator

TYLER CASSIDY¹ and ANTONY R. HUMPHRIES^{1,2}

¹ Department of Mathematics and Statistics, McGill University,
805 Sherbrooke Street West, Montreal, H3A 0B9, Canada.

² Department of Physiology, McGill University,
3655 Promenade Sir-William-Osler, Montreal, H3G 1Y6, Canada.

[Received: Inserted by editor September 27, 2018]

September 27, 2018

Abstract

We develop and analyse a mathematical model of tumour-immune interaction that explicitly incorporates heterogeneity in tumour cell cycle duration by using a distributed delay differential equation. Our necessary and sufficient conditions for local stability of the cancer free equilibrium completely characterise the importance of tumour-immune interaction in disease progression. Consistent with the immunoediting hypothesis, we show that decreasing tumour-immune interaction leads to tumour expansion. Finally, we show that immune involvement is crucial in determining the long-term response to viral therapy.

1 Introduction

Malignant tumours contain a highly heterogeneous population of cells that have distinct genotypes and reproductive abilities [Bell and McFadden, 2014; Lichty et al., 2014]. The heterogeneous nature of tumours is mirrored in the reproduction speed of malignant cells. Most existing mathematical models greatly simplify the impact of heterogeneity in cell cycle times by either neglecting the cell cycle or assuming that all tumour cells have identical cell cycle durations. We will account for the range of cell cycle durations by deriving a mathematical model of tumour growth using a delay differential equation (DDE) with a distribution of delays. This is, to our knowledge, a novel method of considering the heterogeneity present in malignant tumours and presents a physiologically realistic model of tumour expansion.

Distributed DDEs model a continuum of cell cycle durations that belong to an interval of physiologically realistic values, with durations distributed according to a probability density function (PDF). Representing the time length of the cell cycle by a distributed DDE explicitly allows for variability in cell cycle duration. This contrasts with discrete DDEs, where the discrete delay represents the cell cycle duration which is taken to be the same for all tumour cells. Thus discrete delays implicitly assume homogeneity of the tumour cell cycle duration which limits the physiological relevance of such models.

The human immune system attempts to eradicate malignant cells and inhibit tumour establishment [Hallam et al., 2009; Hoos et al., 2011]. We study this phenomenon by explicitly including tumour-immune interaction in our mathematical model. Analysis of this model shows that there is a threshold tumour size below which the immune system successfully prevents tumour establishment and quantifies the role of immune surveillance in tumour establishment and growth.

Therapeutic strategies under development attempt to exploit the immune system to eradicate malignant tumours via immuno-oncology and genetically engineered oncolytic viruses [Cassady et al., 2016; Chiocca and Rabkin, 2015; Hoos et al., 2011; Lawler and Chiocca, 2015]. Oncolytic viruses are designed to exploit the high reproductive rate characteristic of malignant tumours and preferentially infect cancerous cells. Immune regulated death of infected tumour cells releases tumour specific antigens that signal the immune system [Breitbach et al., 2016]. We incorporate oncolytic viral therapy into our mathematical model to study how these viruses can prime the immune system to eliminate tumours.

The release of tumour specific antigens induces a long-lasting immune response that causes tumour regression which persists after resolution of the infection [Bourgeois-Daigneault et al., 2016]. Consequently, oncolytic viruses have recently been recast as instigators of immuno-oncology and are being engineered to induce immune recruitment. For example, in 2015, the United States Food and Drug Administration approved a modified herpes virus that promotes granulocyte-macrophage colony-stimulating factor production and resulting anti-tumour immunity for treatment of melanoma [Bommareddy et al., 2017].

Mathematical models have been used extensively to understand and predict tumour growth and tumour-immune interactions (see Santiago et al. [2017]; Walker and Enderling [2016]; Wodarz [2016] for reviews). Existing models range from formulations as ordinary differential equations (ODEs) [Idema et al., 2010; Kim et al., 2015; Kirschner and Panetta, 1998; MacNamara and Eftimie, 2015], to partial differential equations [Hillen et al., 2013; Malinzi et al., 2017] and discrete DDEs [Liu et al., 2007; Mahasa et al., 2017; Villasana and Radunskaya, 2003].

Crivelli et al. [2012] developed and analysed a discrete DDE model of tumour growth and viral oncology. The Crivelli model is simple enough to be analytically tractable while retaining important physiological aspects of tumour growth and oncolytic viral therapy, but neglects the role of the immune system in tumour eradication. Crivelli et al. [2012] model the interaction of virions and tumour cells by using a non-differentiable function which significantly complicates the analysis of the model. This contact function allows for viral therapy alone to drive tumour remission in their model, without interaction with the immune system.

We develop a tumour growth and viral oncology model which incorporates immune recruitment to drive tumour clearance. Our model is partly based on the Crivelli model but augments and generalises it in very significant ways. We explicitly model phagocytosis of the tumour cells, and cytokine driven phagocyte recruitment. As mentioned, we also include a distribution of cell cycles times for the tumour cells which results in a DDE with distributed delays. The inclusion of a heterogeneous cell cycle duration is more realistic than models with a discrete delay, because a discrete delay is equivalent to assuming that every cell in the tumour has a constant and identical cell cycle duration. We show the explicit link between our work and Crivelli et al. [2012] in Appendix A.

The distributed DDE tumour-immune model is developed in full generality in Section 2. In Section 3, we prove that solutions of the initial value problem evolving from non-negative initial data remain non-negative. Next, in Theorem 3.3, we determine a condition for treatment free extinction of the tumour that quantifies the link between immune involvement and disease progression. Our results show that immune involvement is crucial in controlling tumour growth. As a direct consequence, we show in Corollary 3.4 that homogeneous tumours are less robust than tumours with heterogeneous cell cycle durations. Finally, by showing the existence of a cancer-immune co-existence equilibrium in Theorem 3.5, we establish a direct link between the minimal viable tumour size and the immune killing capacity that is consistent with the immunoediting hypothesis of tumour progression [Mittal et al., 2014]. In Section 4, by deriving a variant of the linear chain technique, we prove that the distributed DDE is equivalent to a finite dimensional ODE. We end Section 4 by simulating viral oncology treatment and illustrating the previously derived stability results. Our simulations show the existence of a transcritical bifurcation where the unstable nonzero equilibrium acts as a separatrix between tumour extinction and growth. Biologically, this result implies that treatment strategies that force the malignant tumour across the separatrix will eradicate the tumour. Moreover, we

show that sufficiently strong immune involvement can counteract aggressive tumour growth and lead to tumour extinction without treatment. Finally, we discuss our results in Section 5.

2 Model Development

Our model of tumour-immune interaction is given by the system of differential equations

$$\left. \begin{aligned} \frac{d}{dt}Q(t) &= 2 \int_{-\infty}^t \exp \left[- \int_{\sigma}^t \hat{d}_K + \eta(U(x)) + \psi_G(U(x)) dx \right] a_2 G_1(\sigma) K(t - \sigma) d\sigma \\ &\quad - a_1 Q(t) - d_1 Q(t) - \psi_Q(U(t)) Q(t) \\ \frac{d}{dt}G_1(t) &= a_1 Q(t) - a_2 G_1(t) - d_2 G_1(t) - \eta(U(t)) G_1(t) - \psi_G(U(t)) G_1(t) \\ \frac{d}{dt}I(t) &= \eta(U(t)) [G_1(t) + N(t)] - \delta I(t) \\ \frac{d}{dt}V(t) &= -\eta(U(t)) [G_1(t) + N(t)] + \alpha [\delta I(t)] - \omega V(t) \\ \frac{d}{dt}C(t) &= C_{prod}(U(t)) - k_{elim} C(t). \\ \frac{d}{dt}P(t) &= \varphi(C(t)) - \gamma_p P(t) \end{aligned} \right\} \quad (1)$$

In equation (1), $Q(t)$ and $G_1(t)$ denote the quiescent and proliferative phase tumour cells. The cytokine concentration is denoted by $C(t)$, and the phagocyte concentration in the tumour microenvironment by $P(t)$. Finally, $V(t)$ is the concentration of oncolytic virions and $I(t)$ is the number of infected tumour cells.

In the Burns and Tannock [1970] model of the cell cycle, $Q(t)$ corresponds to cells in the G_0 phase while $G_1(t)$ corresponds to the G_1 phase. We consider the S , G_2 and M phases to be the active phases of the cell cycle, which we model as a process rather than as populations.

In a similar manner to Crivelli et al. [2012]; Dawson and Hillen [2006] and Liu et al. [2007], we use a constant transition rate from G_0 to G_1 . The G_1 - S and the G_2 - M checkpoints have been explored as targets of emerging cancer treatment [Dominguez-Brauer et al., 2015; Matheson et al., 2016; Visconti et al., 2016]. By separating the G_1 phase from the S , G_2 and M phases, our model could be easily adapted to include the precise effects of interventions that arrest the cell cycle at the G_1 - S checkpoint, such as cyclin dependent kinase inhibitors [Dominguez-Brauer et al., 2015]. It would also be possible to incorporate drug induced cell cycle arrest at the G_2 - M checkpoint by decreasing mitotic output (without effecting transition across the G_1 - S checkpoint), similar to emerging treatments discussed by Dominguez-Brauer et al. [2015]; Visconti et al. [2016].

We denote by $N(t)$ the total number of cells in the active portion (the S , G_2 and M phases) of the cell cycle, given by

$$N(t) = \int_0^\infty a_2 G_1(t - \xi) \exp \left[- \int_{t-\xi}^t \hat{d}_K + \psi_G(U(x)) + \eta(U(x)) dx \right] \left(1 - \int_0^\xi K(\sigma) d\sigma \right) d\xi, \quad (2)$$

as derived in Appendix B. In equations (1) and (2) the distribution of the duration of the active phase of the cell cycle is described by the PDF $K(t)$. We do not choose a specific distribution in our model; see Section 2.1 for a discussion of the properties of $K(t)$.

The functions $\eta(U(t))$, $\psi_Q(U(t))$, $\psi_G(U(t))$, $\varphi(C(t))$, and $C_{prod}(U(t))$ in equation (1) are defined in equations (8), (10), (11) and (13). To simplify notation, we denote the vector

$$U(t) = [Q(t), G_1(t), I(t), V(t), C(t), P(t)].$$

The distributed DDE is given initial data $Q(t_0)$, $I(t_0)$, $C(t_0)$ and $[G_1(s), V(s), P(s)] = [\phi_G(s), \phi_V(s), \phi_P(s)]$ for $s \in (-\infty, t_0]$ for integrable functions $\phi_G(s)$, $\phi_V(s)$, $\phi_P(s)$ to create an initial value problem. For simplicity, we take $t_0 = 0$.

Figure 1: Pictorial representation of the tumour growth model. Populations are denoted by circles, processes by squares and rates by arrows. Quiescent cells enter $G_1(t)$ at rate a_1 and undergo apoptosis at rate d_1 . Cells leave $G_1(t)$ and enter the active phase of the cell cycle at rate a_2 while undergoing apoptosis at a rate d_2 . The active phase death rate is $\hat{d}_k$ and cells re-enter quiescence after mitosis. Phagocytes interact with quiescent and G_1 phase cells at respective rates ψ_Q and ψ_G . Tumour-immune interaction drives cytokine production through the function C_{prod} .

We derive equation (1) in three steps. First, we consider tumour growth in the absence of immune interaction and viral therapy in Section 2.1. Tumour heterogeneity is explicitly accounted for by using a distributed cell cycle time length. The tumour growth equations are derived keeping in mind the eventual use of the model to describe the impact of an RNA oncolytic virus on tumour growth. Next, in Section 2.2, we derive the tumour-immune interaction and incorporate immunosurveillance into the tumour growth model. The graphical representation of the tumour-immune growth model is given in Figure 1. Finally, by including viral therapy and immune recruitment in Section 2.3, we arrive at equation (1).

2.1 Tumour Growth Model Development

RNA viruses replicate in infected cells during stages G_1 through M of the Burns and Tannock [1970] model of the cell cycle. As previously noted, we separately model the quiescent ($Q(t)$) and G_1 phase ($G_1(t)$) tumour cell populations. Quiescent tumour cells undergo apoptosis at a rate d_1 . We denote the transit rate between the quiescent and G_1 population as a_1 . Cells in G_1 undergo apoptosis at a rate d_2 , and enter into the active phase of the cell cycle at a rate a_2 . We define the cell cycle duration as the time length of the active portion of the cell cycle, calculated as the time a cell takes between exiting G_1 and re-entering Q .

We assume that the cell cycle time of tumour cells is a positive random variable with PDF $K(t)$ satisfying

$$K(t) \geq 0 \quad \forall t \in [0, \infty), \quad \int_0^\infty K(t) dt = 1.$$

We assume that cells have an expected mean cell cycle duration of τ , so the expected value of $K(t)$ satisfies

$$\mathbb{E}_K(t) := \int_0^\infty t K(t) dt = \tau < \infty. \quad (3)$$

We will also use that

$$\mathbb{E}_K(f(t)) = \int_0^\infty f(t)K(t)dt, \quad (4)$$

where in particular we note that the Laplace transform $\mathcal{L}[K](\lambda)$ of the PDF $K(t)$ is equivalent to $\mathbb{E}_K(e^{-\lambda t})$ since

$$\mathcal{L}[K](\lambda) := \int_0^\infty e^{-\lambda t}K(t)dt = \mathbb{E}_K(e^{-\lambda t}). \quad (5)$$

Let $A_R(t)$ denote the rate that successfully dividing cells re-enter quiescence at time t . Such cells began the active portion of the cell cycle some time σ in the past at rate $a_2G_1(\sigma)$. The likelihood that these cells complete the cell cycle at time t is given by $K(t - \sigma)$. Disregarding immune interaction for now, cells in the active portion of the cell cycle undergo apoptosis at a constant, distribution specific, rate $\hat{d}_K$. Consequently, cells that spend more time in the active phase of the cell cycle are more likely to undergo apoptosis instead of completing the cell cycle and returning to quiescence. Thus

$$A_R(t) = 2 \int_{-\infty}^t \exp \left[- \int_{\sigma}^t \hat{d}_K dx \right] a_2G_1(\sigma)K(t - \sigma)d\sigma. \quad (6)$$

Later, we will update $A_R(t)$ to include tumour-immune interaction and viral therapy. The distributed delay expression $A_R(t)$ is a novel model of tumour cell reproduction which is more physiologically appropriate than a discrete delay.

The discrete delay model considered by Crivelli et al. [2012] corresponds to $K(t) = \delta(t - \tau)$ and $d_\delta = d_3$. The explicit link between equation (1) and the Crivelli model is shown in Appendix A. The expected cellular output of the cell cycle with a discrete and fixed duration is

$$\mathbb{E}_\delta[te^{-d_3t}] = \tau e^{-d_3\tau}.$$

To ensure a consistent cellular output from the cell cycle for different distributions $K(t)$, we define $\hat{d}_K > 0$ as the distribution dependent unique positive value that solves

$$\mathbb{E}_K[te^{-\hat{d}_K t}] = \tau e^{-d_3\tau}. \quad (7)$$

The parameter $\hat{d}_K$ must exist for a given distribution K as the function

$$f_K(\zeta) = \mathbb{E}_K[te^{-\zeta t}] - \tau e^{-d_3\tau}$$

is continuous and satisfies

$$f_K(0) = \tau(1 - e^{-d_3\tau}) > 0 \quad \text{and} \quad \lim_{\zeta \rightarrow \infty} f_K(\zeta) = -\tau e^{-d_3\tau} < 0.$$

The intermediate value theorem along with the fact that $f(\zeta)$ is strictly decreasing for $\zeta > 0$ guarantees the existence and uniqueness of $\hat{d}_K$.

The resulting model of tumour growth without immunosurveillance is then

$$\begin{aligned} \frac{d}{dt}Q(t) &= A_R(t) - a_1Q(t) - d_1Q(t) \\ \frac{d}{dt}G_1(t) &= a_1Q(t) - a_2G_1(t) - d_2G_1(t), \end{aligned}$$

where $A_R(t)$ is given by (6).

2.2 Immune Model Development

The tumour microenvironment is complex and contains a multitude of cytokines and cell types [Bartlett et al., 2013; Cassady et al., 2016; Grivennikov and Karin, 2011; Hallam et al., 2009]. To avoid overcomplicating the model by adding variables and creating equations corresponding to each cytokine and signalling pathway, we instead model a general local proinflammatory cytokine compartment $C(t)$. We assume the cytokine is produced at a variable rate $C_{prod}(U(t))$ with the homeostatic production rate C_{prod}^* . The viral and immune mediated destruction of tumour cells results in increased cytokine production by releasing tumour specific antigens [Bartlett et al., 2013; Bell and McFadden, 2014]. Conversely, we do not consider apoptosis of tumour cells to be immunogenic [Bartlett et al., 2013]. Therefore, $C_{prod}(U(t))$ is an increasing function of viral and immune destruction of tumour cells. The resulting positive feedback loop is consistent with self activation of immune cells observed experimentally [Mosser, 2003]. Finally, we assume that the cytokine is cleared linearly at rate k_{elim} , mimicking the dynamics of many endogeneous cytokines [Craig et al., 2016; Krzyzanski et al., 2010; Piscitelli et al., 1997]. The simplified cytokine dynamics are thus given by

$$\frac{d}{dt}C(t) = C_{prod}(U(t)) - k_{elim}C(t).$$

We assume that phagocytes can undergo phagocytosis multiple times, so phagocyte clearance is linear, and we do not include a phagocytosis related death term. Inflammatory cytokines drive phagocyte recruitment and activation [Bartlett et al., 2013; Cassady et al., 2016; Hallam et al., 2009]. Consequently, we model the local phagocyte population in a similar cytokine driven manner to Schirm et al. [2016] by using a Michaelis-Menten growth function $\varphi(C(t))$ with maximal production rate k_{cp} and half effect concentration of cytokine $C_{1/2}$. The phagocyte dynamics are therefore given by

$$\frac{d}{dt}P(t) = \varphi(C(t)) - \gamma_p P(t), \quad \text{where} \quad \varphi(C(t)) = \frac{k_{cp}C(t)}{C_{1/2} + C(t)}. \quad (8)$$

The disease free equilibrium concentrations of $(C(t), P(t))$ represent the tumour-free tissue concentrations of cytokine and phagocytes and are given by

$$C^* = \frac{C_{prod}^*}{k_{elim}} \quad \text{and} \quad P^* = \frac{1}{\gamma_p} \frac{k_{cp}C^*}{C_{1/2} + C^*}. \quad (9)$$

We describe phagocyte-tumour cell interaction by

$$\psi_Q(U(t))Q(t) = \frac{k_p P(t)}{1 + k_q Q(t)}Q(t), \quad \text{and} \quad \psi_G(U(t))G_1(t) = \frac{k_p P(t)}{1 + k_s G_1(t)}G_1(t). \quad (10)$$

For small tumour cell populations, the tumour-immune interaction follows mass-action kinetics, while for large tumour cell populations, the phagocytosis rate is limited by the phagocyte concentration as would be expected. We assume that cells in the active portion of the cell cycle interact with the immune system in the same way as cells in the G_1 phase.

The total immune mediated death is then

$$\Psi(U(t)) = \psi_Q(U(t))Q(t) + \psi_G(U(t))(N(t) + G_1(t)).$$

Contact rates similar to equation (10) were derived by Imran and Smith [2007] using a handling time argument.

2.3 Viral Therapy Model Development

Viral infections are caused by virus specific particles, called virions, that infect and replicate in host cells. Infected host cells die after undergoing lysis and releasing virions into the surrounding tissue. To model the effect of oncolytic virus treatment, we consider the virion population, $V(t)$, and the number of infected malignant cells, $I(t)$.

Infection occurs following contact of a virion and a susceptible cell. Susceptible cells are cells in the G_1, S, G_2 and M phases of the cell cycle. We model the infection rate between virions and susceptible cells by $\eta(U(t))$. Infection due to virion and susceptible cell contact occurs in a similar manner to tumour-immune interactions. Consequently, $\eta(U(t))$ is structured similarly to equation (10), with half effect concentration $\eta_{1/2}$ and maximal infectious rate κ , so

$$\eta(U(t)) = \kappa \frac{V(t)}{\eta_{1/2} + V(t)}. \quad (11)$$

As previously noted, disease remission following viral therapy is thought to result from activation of the immune system against the tumour and increased antitumour immunity [Bartlett et al., 2013; Bell and McFadden, 2014; Cassady et al., 2016; Fukuhara et al., 2016; Rehman et al., 2016]. Therefore, introduction of viral therapy alone should not impact the stability of the disease free equilibrium but rather immune response to viral therapy may change the quantitative behaviour of solutions. This is in contrast to Crivelli et al. [2012], who modelled contact between virions and susceptible cells using a non-differentiable contact function. Their choice of contact function was motivated by noting that viral therapy has driven cancer into remission, which implicitly assumed that the virus alone drives disease remission.

Infected tumour cells are produced following infection and undergo lysis at a rate δ . Lysis of infected tumour cells releases α virions. Virions are only produced during lysis and lose infectivity at a rate ω , leading to the differential equations for $I(t)$ and $V(t)$

$$\begin{aligned} \frac{d}{dt} I(t) &= \eta(U(t)) [G_1(t) + N(t)] - \delta I(t) \\ \frac{d}{dt} V(t) &= -\eta(U(t)) [G_1(t) + N(t)] + \alpha \delta I(t) - \omega V(t). \end{aligned}$$

Clearance of proliferating cells leads to exponential loss as the cleared cells no longer divide nor return to quiescence. This is accounted for by updating equation (6) to include the loss of mitotic cells due to immune and viral mediated death, giving

$$A_R(t) = 2 \int_{-\infty}^t \exp \left[- \int_{\sigma}^t \hat{d}_K + \eta(U(x)) + \psi_G(U(x)) dx \right] a_2 G_1(\sigma) K(t - \sigma) d\sigma. \quad (12)$$

Finally, the link between the oncolytic virus and the immune system is cytokine production, modelled by $C_{prod}(U(t))$. Both lysis of infected cells and immune killing are immunogenic, leading to an increase in immune signalling. Therefore, we link virus and immune mediated cell death by the cytokine production rate $C_{prod}(U(t))$, given by

$$C_{prod}(U(t)) = C_{prod}^* + (C_{prod}^{max} - C_{prod}^*) \frac{[\delta I(t) + \Psi(U(t))]}{\Psi_{1/2} + [\delta I(t) + \Psi(U(t))]} \quad (13)$$

We note that $C_{prod}(U(t)) \geq C_{prod}^* > 0$ for nonnegative cell populations; the homeostatic cytokine production rate is effectively the minimal cytokine production rate.

Combining the differential equations for each population with the PDF $K(t)$ gives the complete model in equation (1).

3 Model analysis

The mathematical model in equation (1) represents cell populations which are non-negative quantities. Consequently, we begin our analysis by showing that solutions of equation (1) evolving from non-negative initial data remain non-negative.

Lemma 3.1. *Assume that the parameters in equation (1) are strictly positive and that the initial conditions are componentwise non-negative. Moreover, assume that $G_1(s) = \phi_G(s) \geq 0$ for $s \in (-\infty, 0]$. Then solutions of the initial value problem corresponding to equation (1) are non-negative for all time $t \geq 0$.*

Proof. By the assumption on the initial conditions, $C_{prod}(U(0)) \geq C_{prod}^* > 0$, so

$$\frac{d}{dt}C(t) > -k_{elim}C(t)$$

in a neighbourhood $t \in [0, \varepsilon_C]$. Gronwall's inequality ensures that $C(t) \geq C(0)e^{-k_{elim}t} \geq 0$ for $t \in [0, \varepsilon_C]$. In this interval,

$$-\gamma_p P(t) \leq \frac{d}{dt}P(t) \leq k_{cp} - \gamma_p P(t),$$

therefore

$$0 \leq P(0)e^{-\gamma_p t} \leq P(t) \leq \frac{k_{cp}}{\gamma_p}(1 - e^{-\gamma_p t}) + P(0)e^{-\gamma_p t} \leq \max\left\{\frac{k_{cp}}{\gamma_p}, P(0)\right\} = P^{max}.$$

We now investigate the populations $Q(t)$ and $G_1(t)$. If $Q(0) = G_1(0) = 0$ and $\phi_G(s) = 0$ K -almost everywhere in $(-\infty, 0]$, $Q(t)$ and $G_1(t)$ remain identically zero for all time $t > 0$. If $Q(0) = 0$ and $\phi(s)K(-s) > 0$ on some set of positive measure in $(-\infty, 0]$, then $Q(t)$ eventually becomes positive for some $t > 0$. Therefore, we only need to consider the case where $Q(0) > 0$ and $\phi(s) \geq 0$ for $s \in (-\infty, 0]$.

Now, let $t_g \in [0, \varepsilon_C]$ be the first time that $G_1(t_g) = 0$. Then $A_R(t)$ defined by equation (12) satisfies $A_R(t) \geq 0$ for all $t \in [0, t_g]$. It follows from equation (1) that

$$\frac{d}{dt}Q(t) \geq -(a_1 + d_1 + k_p P^{max})Q(t) \quad \text{for } t \in [0, t_g].$$

Then $Q(t) > 0$ for $t \in [0, t_g]$ and

$$\frac{d}{dt}G_1(t)|_{t=t_g} = a_1 Q(t_g) - a_2 G_1(t_g) - d_2 G_1(t_g) - \eta(U(t))G_1(t_g) - \psi_G(U(t_g))G_1(t_g) = a_1 Q(t_g) > 0. \quad (14)$$

Thus $G_1(t)$ is strictly increasing at t_g . If $t_g = 0$, then $G_1(t) > 0$ immediately. Conversely, if $t_g > 0$, then $G_1(t)$ must be nonincreasing at t_g . This contradicts equation (14), so no such $t_g > 0$ can exist and $G_1(t) > 0$ for $t \in (0, \varepsilon_C]$. Since $A_R(t) \geq 0$ while $G_1(t) \geq 0$, it follows from the arguments above that $Q(t) > 0$ while $G_1(t) \geq 0$. Finally, it is simple to see that $G_1(t) > 0$ for $t \in (0, \varepsilon_C]$ implies that $N(t)$ defined by (2) satisfies $N(t) > 0$ for all $t \in (0, \varepsilon_C]$.

If $V(0) = I(0) = 0$, then the $I(t), V(t)$ populations remain identically zero for all time. Therefore, we consider $V(0) + I(0) > 0$ and we have three cases:

Case I If $V(0) = 0$ then $I(0) > 0$ and it is simple to calculate that

$$\frac{d}{dt}V(t)|_{t=0} = \alpha \delta I(0) > 0,$$

so $V(t)$ becomes strictly positive immediately.

Case II If $I(0) = 0$

If $Q(0) = 0$ and $\phi(s) = 0$ almost everywhere in $(-\infty, 0]$, the tumour free case, then $Q(t), G_1(t)$ and $I(t)$ remain identically zero for all time $t > 0$ and $V(t)$ decays exponentially to 0.

Thus, as above, we need only consider $Q(0) > 0$ and $G_1(t) > 0$ in $(0, \varepsilon_C]$. Now, $I(0) = 0$ so $V(0) > 0$ and for all $t \in (0, \varepsilon_C]$, if $I(t) = 0$ then

$$\frac{d}{dt}I(t) = \eta(U(t)) [G_1(t) + N(t)] > 0$$

and $I(t) > 0$ for all $t \in (0, \varepsilon_C]$, otherwise a contradiction ensues.

Case III Thus, it only remains to consider the case where $V(t)$ and $I(t)$ are both strictly positive immediately and remain positive in some neighbourhood of $t = 0$. While $I(t)$ and $V(t)$ are non-negative, we compute

$$\frac{d}{dt}(I(t) + V(t)) = -(\delta - \alpha\delta)I(t) - \omega V(t) \geq -\max[(\delta - \alpha\delta), \omega](I(t) + V(t)),$$

so

$$V(t) + I(t) \geq [V(0) + I(0)] \exp(-\max[(\delta - \alpha\delta), \omega]t) > 0.$$

If there exists a time t_v such that $V(t_v) = 0$ then $I(t_v) > 0$ and $\frac{d}{dt}V(t)|_{t=t_v} \leq 0$, but arguing as in Case I, we see that $\frac{d}{dt}V(t)|_{t=t_v} > 0$, and hence no such time t_v can exist. Similarly, if there exists a time t_I such that $I(t_I) = 0$ then $V(t_I) > 0$ and $\frac{d}{dt}I(t)|_{t=t_I} \leq 0$, but arguing as in Case II, we see that $\frac{d}{dt}I(t)|_{t=t_I} > 0$, so no such t_I can exist. Therefore, $V(t) > 0$ and $I(t) > 0$ for all $t \in [0, \varepsilon_C]$.

Finally, for $Q(t), G_1(t), I(t), V(t), P(t)$ strictly positive, the cytokine production rate satisfies $C_{prod}(U(t)) \geq C_{prod}^*$, so

$$\frac{d}{dt}C(t) \geq C_{prod}^* - k_{elim}C(t),$$

and $C(t) \geq \left(\frac{C_{prod}^*}{k_{elim}}(1 - e^{-k_{elim}t}) + C(0)e^{-k_{elim}t}\right) > 0$ for all $t \in [0, \varepsilon_C]$. Then, each component is positive at $t = \varepsilon_C$ and the above argument extends from $[0, \varepsilon_C]$ to $[0, \infty)$. $\square$

3.1 Linearisation of the distributed DDE

The system (1) has the cancer free equilibrium (CFE), $U^* = (0, 0, 0, 0, C^*, P^*)$. Although it is often convenient to regard a trajectory $U(t)$ of the system (1) as a parameterised curve with $U(t) \in \mathcal{C}(\mathbb{R}, \mathbb{R}^6)$, it is important to realise that the DDE system (1) defines an infinite dimensional dynamical system. The infinite-dimensional phase space is

$$L^1((-\infty, 0], \mathbb{R}^6, \mu) = \left\{ f : (-\infty, 0] \rightarrow \mathbb{R}^6 \mid \int_0^\infty |f(-s)| d\mu(s) < \infty \right\}$$

where $|\cdot|$ is the ℓ_1 norm in $\mathbb{R}^6$, and μ is a probability measure whose Radon-Nikodym derivative with respect to the Lebesgue measure is $K(t)$. When $K(t)$ is Riemann integrable (such as in the case of the Gamma distribution that we will consider in Section 4) this implies that

$$\mu(t) = \int_0^t K(\xi) d\xi.$$

This space satisfies the axioms given by Hale and Verduyn Lunel [1993]; Hino et al. [1991], so there exists a unique solution to the corresponding initial value problem.

To investigate the long term behaviour of the model, we linearise the system around the CFE in $L_1(\mu)$. In a similar procedure to Câmara De Souza et al. [2018], we first linearise the function $A_R(t)$, given in

equation (12) around the CFE. Using the Taylor expansions of $\eta(U(x))$ and $\psi_G(U(x))$, with $\eta(U^*) = 0$, we approximate the inner integral

$$\begin{aligned} I &= - \int_{t-\sigma}^t \hat{d}_K + \eta(U(x)) + \psi_G(U(x)) dx \\ &= - \int_{t-\sigma}^t \hat{d}_K + \psi_G^* + \eta'(U^*)(U(x) - U^*) + \psi'_G(U^*)(U(x) - U^*) + \mathcal{O}(|U(x) - U^*|^2) dx. \end{aligned}$$

The full expansion of e^I is

$$\begin{aligned} e^I &= e^{-[\hat{d}_K + \psi_G^*]\sigma} \exp \left(- \int_0^\sigma \eta'(U^*)(U(t-x) - U^*) + \psi'_G(U^*)(U(t-x) - U^*) + \mathcal{O}(|U(t-x) - U^*|^2) dx \right) \\ &= e^{-[\hat{d}_K + \psi_G^*]\sigma} \left[1 - \int_0^\sigma \eta'(U^*)(U(t-x) - U^*) + \psi'_G(U^*)(U(t-x) - U^*) dx + \mathcal{O}(|U(t-x) - U^*|^2) \right]. \end{aligned}$$

Importantly, e^I is multiplied by $G_1(t - \sigma)$ in $A_R(t)$ and any non-constant terms of $U(t)$ in the expansion of e^I are consequently nonlinear. So we obtain

$$A_R(t) = 2 \int_0^\infty \exp \left(-[\hat{d}_K + \psi_G^*]\sigma \right) d\sigma + \mathcal{O}(|U(t) - U^*|^2) \quad (15)$$

We translate the CFE of equation (1) to zero by setting $\bar{C}(t) = C(t) - C^*$ and $\bar{P}(t) = P(t) - P^*$ with C^* and P^* given by equation (9). Then, noting that $\eta(U^*) = 0$ and using (15), the $N(t)$ terms in the $I(t)$ and $V(t)$ equations are also nonlinear. Equation (1) becomes

$$\left. \begin{aligned} \frac{d}{dt} Q(t) &= 2 \int_0^\infty \exp \left(-[\hat{d}_K + \psi_G^*]\sigma \right) a_2 G_1(t - \sigma) K(\sigma) d\sigma \\ &\quad - (a_1 + d_1 + k_p P^*) Q(t) + \mathcal{O}(|U(t) - U^*|^2). \\ \frac{d}{dt} G_1(t) &= a_1 Q(t) - (a_2 + d_2 + k_p P^*) G_1(t) + \mathcal{O}(|U(t) - U^*|^2) \\ \frac{d}{dt} I(t) &= -\gamma I(t) + \mathcal{O}(|U(t) - U^*|^2) \\ \frac{d}{dt} V(t) &= \alpha I(t) - \omega V(t) + \mathcal{O}(|U(t) - U^*|^2) \\ \frac{d}{dt} \bar{C}(t) &= \left(\frac{C_{prod}^{max} - C_{prod}^*}{\Psi_{1/2} + k_p P^*} \right) [\delta I(t) + k_p P^* (G_1(t) + Q(t))] - k_{elim}(\bar{C}(t)) + \mathcal{O}(|U(t) - U^*|^2) \\ \frac{d}{dt} \bar{P}(t) &= \frac{k_{cp}}{C_{1/2} + C^*} \bar{C}(t) - \gamma_p \bar{P}(t) + \mathcal{O}(|U(t) - U^*|^2). \end{aligned} \right\} \quad (16)$$

We follow Smith [2011] to complete the linearisation. We define $\mathbf{X}(t) := U(t) - U^*$ and use $\mathbf{X}_\tau$ to denote the linear delayed terms via

$$\mathbf{X}_\tau(t) := \int_0^\infty e^{-[\hat{d}_K + \psi_G^*]\sigma} \mathbf{X}(t - \sigma) K(\sigma) d\sigma.$$

By making the ansatz $\mathbf{X}(t) = \mathbf{C}e^{\lambda t}$, we see that $\mathbf{X}_\tau(t)$ satisfies

$$\mathbf{X}_\tau(t) = \int_0^\infty e^{-[\hat{d}_K + \psi_G^*]\sigma} \mathbf{X}(t - \sigma) K(\sigma) d\sigma = \mathbf{C}e^{\lambda t} \int_0^\infty e^{-(\lambda + \hat{d}_K + \psi_G^*)\sigma} K(\sigma) d\sigma = \mathbf{X}(t) \mathcal{L}[K](\lambda + \hat{d}_K + \psi_G^*),$$

where $\mathcal{L}[K](\lambda)$ is the Laplace transform of $K(\sigma)$ defined by (5).

Dropping the nonlinear terms in equation (16) and setting

$$\xi_c = \frac{(C_{prod}^{max} - C_{prod}^*)}{\Psi_{1/2} + k_p P^*},$$

we obtain the linearised infinite dimensional DDE

$$\frac{d}{dt}\mathbf{X}(t) = \mathbb{A}\mathbf{X}(t) + \mathbb{B}\mathbf{X}_\tau(t) = (\mathbb{A} + \mathcal{L}[K](\lambda + \hat{d}_K + \psi_G^*)\mathbb{B})\mathbf{X}(t), \quad (17)$$

where

$$\mathbb{A} + \mathcal{L}[K](\lambda + \hat{d}_K + \psi_G^*)\mathbb{B} = \left[\begin{array}{cc|cccc} -(a_1 + d_1 + k_p P^*) & 2a_2 \mathcal{L}[K](\lambda + \hat{d}_K + \psi_G^*) & 0 & 0 & 0 & 0 \\ a_1 & -(a_2 + d_2 + k_p P^*) & 0 & 0 & 0 & 0 \\ \hline 0 & 0 & -\delta & 0 & 0 & 0 \\ 0 & 0 & \alpha\delta & -\omega & 0 & 0 \\ \xi_c k_p P^* & \xi_c k_p P^* & \xi_c \delta & 0 & -k_{elim} & 0 \\ 0 & 0 & 0 & 0 & \frac{k_{cp}}{C_{1/2} + C^*} & -\gamma_p \end{array} \right].$$

Hence equation (17) becomes

$$C\lambda e^{\lambda t} = (\mathbb{A} + \mathcal{L}[K](\lambda + \hat{d}_K + \psi_G^*)\mathbb{B})C e^{\lambda t}, \quad (18)$$

From equation (18), the characteristic equation is

$$q(\lambda) := \det \left[\mathbb{A} + \mathcal{L}[K](\lambda + \hat{d}_K + \psi_G^*)\mathbb{B} - \lambda I \right] = 0.$$

Using the block nature of the linearisation matrix gives

$$q(\lambda) = \rho(\lambda)p(\lambda) = 0,$$

where

$$\left. \begin{aligned} \rho(\lambda) &= (\delta + \lambda)(\omega + \lambda)(k_{elim} + \lambda)(\gamma_p + \lambda), \\ p(\lambda) &= 2a_1 a_2 \mathcal{L}[K](\lambda + \hat{d}_K + \psi_G^*) - (a_1 + d_1 + k_p P^* + \lambda)(a_2 + d_2 + k_p P^* + \lambda). \end{aligned} \right\} \quad (19)$$

Here $\rho(\lambda)$ is the determinant of the lower triangular block and has strictly negative real roots. The explicit roots of $\rho(\lambda)$ imply that the stability of the CFE is determined by the roots of $p(\lambda)$.

To study the persistence of small tumours, we characterise the stability of the disease free steady state. Typically, for DDEs, this involves solving a transcendental equation with infinitely many roots. To simplify the following analysis, we first show that the rightmost root of the characteristic equation is real. This result is unsurprising, as a complex rightmost eigenvalue would give rise to spiralling solutions around the CFE, which would become negative, contradicting Lemma 3.1.

Lemma 3.2. *For strictly positive parameters, the rightmost root of $q(\lambda)$ is real.*

Proof. First, we note from (5) that the Laplace transform of a non-negative function f , is a decreasing function of λ . Similarly,

$$\mathcal{L}[K](\lambda + \hat{d}_K + \psi_G^*) = \int_0^\infty e^{-(\lambda + \hat{d}_K + \psi_G^*)\sigma} K(\sigma) d\sigma$$

is decreasing for real λ where it converges. Therefore, as a function of a real variable, $p(\lambda)$ is continuous and $p(\lambda)$ is strictly decreasing for

$$\lambda > \max[-(a_1 + d_1 + k_p P^*), -(a_2 + d_2 + k_p P^*)] := -\Theta.$$

Moreover,

$$p(-\Theta) = 2a_1 a_2 \mathcal{L}[K](-\Theta + \hat{d}_K + \psi_G^*) > 0 \quad \text{and} \quad \lim_{\lambda \rightarrow \infty} p(\lambda) = -\infty,$$

so there is exactly one real root λ^* of $p(\lambda)$ that satisfies $\lambda^* > -\Theta$.

Since $\rho(\lambda)$ has strictly negative real roots, any complex roots, $\nu = \nu_r + i\nu_i$ with $\nu_r \in (-\Theta, \infty)$ and $\nu_i \neq 0$, of the characteristic equation $q(\lambda)$ must solve $p(\nu) = 0$, which we may rewrite as

$$(a_1 + d_1 + k_p P^* + \nu)(a_2 + d_2 + k_p P^* + \nu) = 2a_1 a_2 \mathcal{L}[K](\nu + \hat{d}_K + \psi_G^*). \quad (20)$$

Taking the magnitude of the equality (20) gives

$$[(a_1 + d_1 + k_p P^* + \nu_r)^2 + \nu_i^2][(a_2 + d_2 + k_p P^* + \nu_r)^2 + \nu_i^2]^{1/2} = 2a_1 a_2 |\mathcal{L}[K](\nu + \hat{d}_K + \psi_G^*)|. \quad (21)$$

However,

$$(a_1 + d_1 + k_p P^* + \nu_r)(a_2 + d_2 + k_p P^* + \nu_r) < [(a_1 + d_1 + k_p P^* + \nu_r)^2 + \nu_i^2][(a_2 + d_2 + k_p P^* + \nu_r)^2 + \nu_i^2]^{1/2}$$

and

$$\begin{aligned} 2a_1 a_2 |\mathcal{L}[K](\nu + \hat{d}_K + \psi_G^*)| &= 2a_1 a_2 \left| \int_0^\infty \exp[-(\nu_r + i\nu_i + \hat{d}_K + \psi_G^*)\sigma] K(\sigma) d\sigma \right| \\ &\leq 2a_1 a_2 \int_0^\infty |\exp[-(\nu_r + \hat{d}_K + \psi_G^*)\sigma]| |e^{-i\nu_i \sigma}| d\sigma \\ &= 2a_1 a_2 \int_0^\infty |\exp[-(\nu_r + \hat{d}_K + \psi_G^*)\sigma] K(\sigma)| d\sigma \\ &= 2a_1 a_2 \mathcal{L}[K](\nu_r + \hat{d}_K + \psi_G^*) \end{aligned}$$

where the last equality comes from the nonnegativity of the integrand. Substituting these bounds into equation (21) gives

$$(a_1 + d_1 + k_p P^* + \nu_r)(a_2 + d_2 + k_p P^* + \nu_r) < 2a_1 a_2 \mathcal{L}[K](\nu_r + \hat{d}_K + \psi_G^*),$$

from which we obtain

$$0 = p(\nu_r + i\nu_i) < p(\nu_r).$$

Since $p(\lambda)$ is strictly decreasing for $\lambda > -\Theta$, we must have $\nu_r < \lambda^*$. Then, the rightmost root of $q(\lambda)$ is either λ^* or a root of $\rho(\lambda)$ and is real. $\square$

The preceding result simplifies the analysis of the transcendental characteristic equation by ensuring that the critical characteristic root is real. Therefore, the stability of the CFE, and consequently, the persistence of small tumours, can be characterised using the intermediate value theorem.

Theorem 3.3. *The cancer free equilibrium U^* of equation (1) is locally stable if*

$$2a_1 a_2 \mathcal{L}[K](\hat{d}_K + \psi_G^*) < (a_1 + d_1 + k_p P^*)(a_2 + d_2 + k_p P^*) \quad (22)$$

and unstable if

$$2a_1 a_2 \mathcal{L}[K](\hat{d}_K + \psi_G^*) > (a_1 + d_1 + k_p P^*)(a_2 + d_2 + k_p P^*).$$

Proof. The condition for stability is equivalent to $p(0) < 0$. In this case, since $p(\lambda)$ is strictly decreasing for $\lambda > \max[-(a_1 + d_1 + k_p P^*), -(a_2 + d_2 + k_p P^*)]$, there can be no real root of the characteristic equation with non-negative real part. Since the rightmost root must be real, all roots of the characteristic equation must have negative real part and the CFE is stable.

The condition for instability is equivalent to $p(0) > 0$. Since

$$\lim_{\lambda \rightarrow \infty} p(\lambda) = -\infty,$$

the intermediate value theorem ensures that there is a root of the characteristic equation in the positive half plane and the CFE is unstable. $\square$

Using (5) we can rewrite the stability condition (22) as

$$2a_1a_2 \mathbb{E}_K(\exp(-[\hat{d}_K + \psi_G^*]t)) < (a_1 + d_1 + k_p P^*)(a_2 + d_2 + k_p P^*). \quad (23)$$

This can be rearranged as a basic reproduction number type condition

$$\underbrace{\left[\frac{2a_2 \mathbb{E}_K(\exp(-[\hat{d}_K + \psi_G^*]t))}{a_1 + d_1 + k_p P^*} \right]}_{\text{Rate out of quiescence}} \underbrace{\left[\frac{a_1}{a_2 + d_2 + k_p P^*} \right]}_{\text{Rate out of } G_1} < 1.$$

Hence, the CFE is locally attracting if the product of the ratios of expected transit rates into and out of the quiescent and G_1 phases is less than one. Biologically, this corresponds to each cell that transits out of either the quiescence or G_1 phase not replacing itself through mitosis.

Finally, we can characterise the importance of heterogeneity in cell cycle duration as a determining factor of disease progression. Let $\mathcal{P}$ be the parameter space of the distributed DDE (1). Following Campbell and Jessop [2009], for each PDF $K(t)$, we define the stability region as

$$\Omega_K = \{\mathbf{p} \in \mathcal{P} \mid \text{The CFE of (1) is locally asymptotically stable}\}.$$

Then, we are able to characterise the stability regions for certain PDFs with respect to the discrete DDE. For these PDFs, the tumour heterogeneity in cell cycle duration acts to destabilise the CFE and leads to more a robust tumour. We formalise this relationship in the following corollary.

Corollary 3.4. *For any PDF $K(t)$ which satisfies (3) and $\hat{d}_K \leq d_3$ we have the inclusion $\Omega_K \subseteq \Omega_\delta$.*

Proof. Take $\mathbf{p} \in \Omega_K$ so that equation (23) is satisfied and the CFE is locally stable. Now, we define

$$h_K(x) = \exp(-[\hat{d}_K + \psi_G^*]x).$$

It is simple to see that $h_K(x)$ is convex. Jensen's inequality gives

$$\exp(-[\hat{d}_K + \psi_G^*]\tau) = h_K\left(\int_0^\infty xK(x)dx\right) \leq \int_0^\infty \exp(-[\hat{d}_K + \psi_G^*]x) K(x)dx = \mathbb{E}_K(\exp(-(\hat{d}_K + \psi_G^*)t)).$$

Now, using $\hat{d}_K \leq d_3$, we have

$$\mathbb{E}_\delta(\exp(-(\hat{d}_K + \psi_G^*)t)) = \exp(-[d_3 + \psi_G^*]\tau) \leq \exp(-[\hat{d}_K + \psi_G^*]\tau) \leq \mathbb{E}_K(\exp(-(\hat{d}_K + \psi_G^*)t)).$$

It follows that

$$\mathbb{E}_\delta(\exp(-(\hat{d}_K + \psi_G^*)t)) - (a_1 + d_1 + k_p P^*)(a_2 + d_2 + k_p P^*) < 0,$$

so the CFE is stable in the discrete DDE case and $\mathbf{p} \in \Omega_\delta$. $\square$

The condition $\hat{d}_K \leq d_3$ corresponds to

$$\int_0^\infty t e^{-d_3 t} K(t) dt - \tau e^{-d_3 \tau} \leq 0,$$

which can be viewed as a measure of the skewness of the PDF $K(t)$. Using equation (3), this condition is satisfied if

$$\int_0^\tau t (e^{-d_3 t} - e^{-d_3 \tau}) K(t) dt \leq \left| \int_\tau^\infty t (e^{-d_3 t} - e^{-d_3 \tau}) K(t) dt \right| = \int_\tau^\infty t (e^{-d_3 \tau} - e^{-d_3 t}) K(t) dt.$$

It is important to note that the linearisation only determines local stability. So, while small tumours may not grow, large tumours do not necessarily disappear. In fact, for a given level of immune recognition of tumour cells, k_p , there is a critical tumour size above which the tumour grows unboundedly. The critical tumour size acts as a separatrix between tumour extinction and growth and takes the form of a nonzero equilibrium point where tumour growth and immune surveillance are balanced. In Theorem 3.5, we show that such an equilibrium must exist. Transition across this equilibrium has been hypothesised to occur as part of the cancer immunoediting process that allows tumours to grow and corresponds to a transient decrease of k_p [Bhatia and Kumar, 2011; Mittal et al., 2014; Swann and Smyth, 2007].

To emphasise the biological interpretation of Theorem 3.5, we use the stability condition as written in equation (23) to characterise the existence of the non-zero equilibrium.

Theorem 3.5. *Assume that the parameters in equation (1) are nonnegative. Let k_p^{crit} solve*

$$2a_1a_2\mathbb{E}_K[\exp(-[\hat{d}_k + k_p^{crit}P^*]\sigma) - (a_1 + d_1 + k_p^{crit}P^*)(a_2 + d_2 + k_p^{crit}P^*)] = 0.$$

Then, for $k_p > k_p^{crit}$, there exists a strictly positive untreated equilibrium solution $\bar{Y}_1^ = (\bar{Q}, \bar{G}_1, 0, 0, \bar{C}, \bar{P})$ of equation (1) with Q_1 and G_1 strictly positive.*

Proof. First, in the absence of viral treatment, $V(0) = 0$ and $I(0) = 0$, so $(V^*, I^*) = (0, 0)$.

To simplify notation in the proof, we set $\xi_i = a_i + d_i + k_p P^*$ for $i = 1, 2$. We consider the differential equation for $G_1(t)$ at equilibrium, so $\frac{d}{dt}G_1(t) = 0$ and

$$a_1Q^* = G_1^* \left(a_2 + d_2 + \frac{k_p P^*}{1 + k_s G_1^*} \right).$$

This can be rearranged as a quadratic equation in G_1^* ,

$$(a_2 + d_2)k_s(G_1^*)^2 + (\xi_2 - k_s a_1 Q^*)G_1^* - a_1 Q^* = 0,$$

whose positive root is a function of Q^* defined by

$$G_1^*(Q^*) = \frac{k_s a_1 Q^* - \xi_2 + \sqrt{(k_s a_1 Q^*)^2 + 2(a_2 + d_2 - k_p P^*)k_s a_1 Q^* + \xi_2^2}}{2(a_2 + d_2)k_s}. \quad (24)$$

Now, inserting $G_1^*(Q^*)$ into $\frac{d}{dt}Q(t) = 0$ gives

$$0 = 2a_2 G_1^*(Q^*) \int_0^\infty \exp\left[-\left(\hat{d}_K + \eta(U^*)\right) + \psi_G(U^*)\right] \sigma dx \Big] K(\sigma) d\sigma - (a_1 + d_1 + \psi_Q(U^*))Q^*.$$

Using (4) gives

$$F(Q^*) = 2a_2 G_1^*(Q^*) \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)] - \left(a_1 + d_1 + \frac{k_p P^*}{1 + k_q Q^*}\right) Q^* = 0.$$

We write

$$F(Q^*) = \frac{f(Q^*)}{1 + k_q Q^*}$$

where

$$\begin{aligned} f(Q^*) = & k_q \left(\frac{a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{a_2 + d_2} - (a_1 + d_1) \right) (Q^*)^2 + \frac{a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{a_2 + d_2} Q^* \\ & + \frac{a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{k_s(a_2 + d_2)} \left(-\xi_2 + \sqrt{(k_s a_1 Q^*)^2 + 2(a_2 + d_2 - k_p P^*)k_s a_1 Q^* + \xi_2^2} \right) k_q Q^* \\ & - \xi_1 Q^* + \frac{a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{k_s(a_2 + d_2)} \left(-\xi_2 + \sqrt{(k_s a_1 Q^*)^2 + 2(a_2 + d_2 - k_p P^*)k_s a_1 Q^* + \xi_2^2} \right). \end{aligned}$$

The equilibrium concentration Q_1 must therefore solve $f(Q_1) = 0$. A simple calculation shows that $f(0) = 0$, so we search for Q_1 positive. Now, as $Q^* \rightarrow \infty$,

$$f(Q^*) = \left(\frac{a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{a_2 + d_2} - (a_1 + d_1) \right) k_q (Q^*)^2 + k_q Q^* \frac{a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{k_s(a_2 + d_2)} \sqrt{(k_s a_1 Q)^2 + 2(a_2 + d_2 - k_p P^*) k_s a_1 Q + \xi_2^2} + \mathcal{O}([Q^*]^{3/2}).$$

This is equivalent to

$$f(Q^*) = \left[2a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)] - (a_1 + d_1)(a_2 + d_2) \right] \frac{k_q (Q^*)^2}{(a_2 + d_2)} + \mathcal{O}([Q^*]^{3/2}) \quad \text{as } Q^* \rightarrow \infty,$$

so the sign of $\left[2a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)] - (a_1 + d_1)(a_2 + d_2) \right]$ determines the sign of $f(Q^*)$ as Q^* grows infinitely large. Now,

$$2a_1 a_2 \mathbb{E}_K[e^{-(\hat{d}_k + \psi_G(U^*))\sigma}] - (a_1 + d_1)(a_2 + d_2) > 2a_1 a_2 \mathbb{E}_K[e^{-(\hat{d}_k + k_p^{crit} P^*)\sigma}] - (a_1 + d_1 + k_p^{crit} P^*)(a_2 + d_2 + k_p^{crit} P^*) = 0,$$

so $f(Q^*)$ grows infinitely large with Q^* and must be positive for large values of Q^* .

Next, as $Q^* \rightarrow 0$,

$$f(Q^*) = \frac{a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{k_s(a_2 + d_2)} \left(-\xi_2 + \sqrt{(k_s a_1 Q)^2 + 2(a_2 + d_2 - k_p P^*) k_s a_1 Q + \xi_2^2} \right) + \frac{a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{a_2 + d_2} Q^* - \xi_1 Q^* + \mathcal{O}([Q^*]^{3/2}).$$

Taylor expanding the square root about the point $Q^* = 0$ gives

$$-\xi_2 + \sqrt{(k_s a_1 Q)^2 + 2(a_2 + d_2 - k_p P^*) k_s a_1 Q + \xi_2^2} = -\xi_2 + \sqrt{\xi_2^2} + \frac{(a_2 + d_2 - k_p P^*) k_s a_1 Q}{\xi_2} + \mathcal{O}([Q^*]^2),$$

so for Q^* near 0,

$$f(Q^*) = \frac{a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{a_2 + d_2} Q^* - \xi_1 Q^* + \frac{a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)]}{k_s(a_2 + d_2)} \frac{(a_2 + d_2 - k_p P^*) k_s a_1 Q}{\xi_2} + \mathcal{O}([Q^*]^{3/2}).$$

Crucially, $a_2 + d_2 - k_p P^* = 2(a_2 + d_2) - \xi_2$, so with $f(0) = 0$

$$f'(0) = \lim_{Q^* \rightarrow 0} \frac{f(Q^*)}{Q^*} = \frac{1}{\xi_2} \left[2a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)] - \xi_1 \xi_2 \right].$$

Thus, the sign of $f'(0)$ is determined by the sign of

$$g(k_p) = 2a_1 a_2 \mathbb{E}_K[\exp(-(\hat{d}_k + \psi_G(U^*))\sigma)] - \xi_1 \xi_2.$$

The function $g(k_p)$ is strictly decreasing with $g(k_p^{crit}) = 0$, therefore, $f'(0) < 0$ for $k_p > k_p^{crit}$.

Consequently, $f(Q^*)$ is negative for Q^* small and positive, and positive for large Q^* , so there must be a positive root $\bar{Q}$ with $f(\bar{Q}) = 0$. This root defines a solution $\bar{G}_1 = G_1^*(Q_1)$ of equation (24).

Finally, we can write an equilibrium solution of $\frac{d}{dt}P(t) = 0$ as a function of $C(t)$ via

$$\bar{P} = \frac{\varphi(C(t))}{\gamma_p} \leq \frac{k_{cp}}{\gamma_p}.$$

Given the upper bound of $\bar{P}$ and the pair $(\bar{Q}, \bar{G}_1)$, the function $\Psi(U(t))$ is bounded. Therefore, there must exist a solution $\bar{C} > 0$ to

$$0 = C_{prod}(\bar{Q}, \bar{G}_1, \varphi(\bar{C})/\gamma_p) - k_{elim}\bar{C}.$$

Finally, using the value of $\bar{C}$, we can calculate the corresponding equilibrium $\bar{P}$. $\square$

4 The Gamma Distribution and Equivalent ODE System

To translate our results for a generic distribution into predictions of tumour growth, we must specify a distribution of cell cycle durations, corresponding PDF $K(t)$, and death rate $\hat{d}_K$. We assume that cell cycle durations follow a gamma distribution, so $K(t) = g_a^j(t)$. The function $g_a^j(t)$ is the PDF of the gamma distribution with

$$g_a^j(t) = \frac{a^j t^{j-1} e^{-at}}{\Gamma(j)} \quad \text{with} \quad \frac{d}{dt}g_a^1(t) = -ag_a^1(t) \quad \text{and} \quad \frac{d}{dt}g_a^j(t) = a[g_a^{j-1}(t) - g_a^j(t)], \quad j \geq 2. \quad (25)$$

The real positive parameters a and j in equation (25) define the shape of the gamma distribution. The expected cell cycle duration is $\tau = j/a$. For given τ we take j to be a strictly positive integer and determine a by $a = j/\tau$. The standard deviation, s^2 , of the gamma distribution is given by $s^2 = \tau^2/j$. For fixed τ , larger values of j result in a more concentrated distribution about τ . In Appendix A we demonstrate that in the limit as $j \rightarrow \infty$ (with fixed τ) the gamma distributed model converges in distribution to a delta distributed model with discrete delay τ .

To calculate $\hat{d}_g$, we note that the expected cellular output of the cell cycle is

$$\mathbb{E}_g(\sigma) = \int_0^\infty \sigma e^{-\int_{t-\sigma}^t \hat{d}_g dx} g_a^j(\sigma) d\sigma = \frac{a^j}{\Gamma(j)} \int_0^\infty \sigma^{j+1-1} e^{-(a+\hat{d}_g)\sigma} d\sigma = \frac{a^j}{(a+\hat{d}_g)^{j+1}} j = \left[\frac{a}{a+\hat{d}_g} \right]^{j+1} \frac{j}{a}.$$

Imposing the equality (7) and $\tau = j/a$ gives

$$\left(\frac{1}{1 + \hat{d}_g \tau / j} \right)^{j+1} \tau = \tau e^{-d_3 \tau}.$$

Therefore, $\hat{d}_g$ is given by

$$\hat{d}_g = \frac{j}{\tau} \left[(e^{d_3 \tau})^{1/j+1} - 1 \right]. \quad (26)$$

4.1 Equivalent ODE Formulation

The link between gamma distributed DDEs and transit chain ODEs has been known since at least the 1960s [Vogel, 1961]. The equivalence between infinite dimensional DDEs and ODEs is typically established through the linear chain technique. Among many other areas, the linear chain technique has recently been used in the pharmaceutical sciences [Câmara De Souza et al., 2018; Hu et al., 2018]. More generally, the equivalence between distributed DDEs and ODEs was studied by Diekmann et al. [2017].

Typical applications of the linear chain technique involve a transit chain type ODE without growth or loss throughout the chain. In the example of cellular growth represented by a transit chain model, the number of cells is conserved throughout the delayed process. Here, we derive a variant of the linear chain technique that accounts for the exponential decay of the mitotic cell population due to apoptosis, immune pressure and lysis as modelled in equation (1). The resulting ODE system is a compartment model with linear clearance throughout the transit chain.

By taking $K(t) = g_a^j(t)$ with $j \in \mathbb{N}$ and $a = k_{tr} = j/\tau$ and setting

$$A_i(t) = \int_{-\infty}^t \frac{a_2}{k_{tr}} e^{-\int_{\sigma}^t \hat{d}_g + \eta(U(x)) + \psi_G(U(x)) dx} G_1(\sigma) g_{k_{tr}}^i(t - \sigma) d\sigma \quad \text{for } i = 1, 2, \dots, j,$$

we can reduce the distributed DDE model to a system of ODEs. We show in Theorem 4.2 that equation (1) is equivalent to the system of ODEs

$$\left. \begin{aligned} \frac{d}{dt} Q(t) &= 2k_{tr} A_j(t) - a_1 Q(t) - d_1 Q - \psi_Q(U(t)) Q(t) \\ \frac{d}{dt} G_1(t) &= a_1 Q(t) - a_2 G_1(t) - d_2 G_1(t) - \psi_G(U(t)) G_1(t) - \eta(U(t)) G_1(t) \\ \frac{d}{dt} A_1(t) &= a_2 G_1(t) - k_{tr} A_1(t) - [\hat{d}_g + \eta(U(t)) + \psi_G(U(t))] A_1(t) \\ \frac{d}{dt} A_i(t) &= k_{tr} (A_{i-1}(t) - A_i(t)) - [\hat{d}_g + \eta(U(t)) + \psi_G(U(t))] A_i(t) \quad \text{for } i = 2, 3, \dots, j \\ \frac{d}{dt} I(t) &= -\delta I(t) + \eta(U(t)) [G_1(t) + N(t)] \\ \frac{d}{dt} V(t) &= \alpha \delta I(t) - \omega V(t) - \eta(U(t)) [G_1(t) + N(t)] \\ \frac{d}{dt} C(t) &= C_{prod}(U(t)) - k_{elim} C(t) \\ \frac{d}{dt} P(t) &= \varphi(C(t)) - \gamma_p P(t) \end{aligned} \right\} \quad (27)$$

with identical initial conditions to the distributed DDE for $Q(0), V(0), I(0), P(0), C(0)$ and

$$G_1(0) = \phi(0), \quad A_i(0) = \int_0^\infty \frac{a_2}{k_{tr}} e^{-\int_{-\sigma}^0 \hat{d}_g + \eta(U(x)) + \psi_G(U(x)) dx} \phi(-\sigma) g_{k_{tr}}^i(\sigma) d\sigma,$$

where $\phi(s)$ is the history function of equation (1).

Lemma 4.1. *For an integrable function $G_1(t)$ and $j \in \mathbb{N}$ with $a = k_{tr} = j/\tau$, the vector with i -th component given by*

$$A_i(t) = \int_{-\infty}^t e^{-\int_{\sigma}^t \hat{d}_g + \eta(U(x)) + \psi_G(U(x)) dx} \frac{a_2}{k_{tr}} G_1(\sigma) g_{k_{tr}}^i(t - \sigma) d\sigma \quad \text{for } i = 1, 2, \dots, j, \quad (28)$$

is the solution of the system of differential equations given by

$$\left. \begin{aligned} \frac{d}{dt} A_1(t) &= a_2 G_1(t) - k_{tr} A_1(t) - [\hat{d}_g + \eta(U(t)) + \psi_G(U(t))] A_1(t) \\ \frac{d}{dt} A_i(t) &= k_{tr} (A_{i-1}(t) - A_i(t)) - [\hat{d}_g + \eta(U(t)) + \psi_G(U(t))] A_i(t) \quad \text{for } i = 2, 3, \dots, j \end{aligned} \right\} \quad (29)$$

Proof. Using the Leibniz and product rules, we differentiate $A_1(t)$ to obtain

$$\begin{aligned} \frac{d}{dt} A_1(t) &= a_2 G_1(t) - k_{tr} \int_{-\infty}^t \frac{a_2}{k_{tr}} e^{-\int_{\sigma}^t \hat{d}_g + \eta(U(x)) + \psi_G(U(x)) dx} G_1(\sigma) g_{k_{tr}}^1(t - \sigma) d\sigma \\ &\quad + \int_{-\infty}^t \frac{d}{dt} e^{-\int_{\sigma}^t \hat{d}_g + \eta(U(x)) + \psi_G(U(x)) dx} \frac{a_2}{k_{tr}} G_1(\sigma) g_{k_{tr}}^1(t - \sigma) d\sigma. \end{aligned} \quad (30)$$

Computing the derivative of the exponential then gives

$$\frac{d}{dt}A_1(t) = a_2G_1(t) - k_{tr}A_1(t) - [\hat{d}_g + \eta(U(t)) + \psi_G(U(t))]A_1. \quad (31)$$

Similarly for general i , differentiating the expression for $A_i(t)$ from (28) gives

$$\begin{aligned} \frac{d}{dt}A_i(t) &= \frac{a_2}{k_{tr}}e^0G_1(t)g_a^i(0) + \int_{-\infty}^t \frac{a_2}{k_{tr}} \frac{d}{dt} [e^{-\int_{\sigma}^t \hat{d}_g + \eta(U(x)) + \psi_G(U(x))dx} G_1(\sigma)g_{k_{tr}}^i(t - \sigma)]d\sigma \\ &= k_{tr}(A_{i-1}(t) - A_i(t)) - [\hat{d}_g + \eta(U(t)) + \psi_G(U(t))]A_i(t). \end{aligned}$$

Thus, the vector $\mathbf{A}(t) = [A_1(t), A_2(t), \dots, A_j(t)]$ satisfies equation (29). $\square$

Comparing equations (30) and (31) shows that the exponential loss of cells during the cell cycle in equation (1) corresponds to linear clearance in the equivalent transit compartment system of ODEs.

We now show the equivalence of the ODE and DDE models by using Lemma 4.1 to replace the integral terms in equation (1).

Theorem 4.2. *The system of distributed DDEs (1) with $K(\sigma) = g_a^j(\sigma)$, $\hat{d}_g$ as given in (26) and initial conditions $Q(0) = Q_0$, $I(0) = I_0$, $C(0) = C_0$ and history functions $V(s) = \phi_V(s)$, $P(s) = \phi_P(s)$ and $G_1(s) = \phi_G(s)$ for $s \in (-\infty, 0]$ is equivalent to the system of ODEs (27) with initial conditions $Q(0) = Q_0$, $I(0) = I_0$, $C(0) = C_0$, $V(0) = \phi_V(0)$, $P(0) = \phi_P(0)$, $G_1(0) = \phi_G(0)$ and*

$$A_i(0) = \int_0^\infty \frac{a_2}{k_{tr}} \exp \left[- \int_{-\sigma}^0 \hat{d}_g + \eta(U(x)) + \psi_G(U(x))dx \right] \phi_G(-\sigma)g_{k_{tr}}^i(\sigma)d\sigma. \quad (32)$$

Proof. Using Lemma 4.1, we see that

$$2k_{tr}A_j(t) = 2 \int_{-\infty}^t a_2 \exp \left[- \int_{\sigma}^t \hat{d}_g + \eta(U(x)) + \psi_G(U(x))dx \right] G_1(\sigma)g_{k_{tr}}^j(t - \sigma)d\sigma = A_R(t).$$

Thus, the differential equations for $Q(t)$ in (1) and (27) are equivalent.

The remaining terms in equation (27) are exactly those in equation (1). To finish the conversion from the DDE (1) to the ODE (27), we must specify the initial conditions. Given the history functions $[\phi_G(s), \phi_V(s), \phi_P(s)]$ from the DDE model, we chose the initial conditions $A_i(0)$ of equation (27) according to equation (32). This ensures that the solution of equation (27) is equivalent to the solution of equation (1) [Smith, 2011].

To convert from the ODE (27) to the DDE (1), we must take care with the construction of the history functions $(\phi_G(s), \phi_V(s), \phi_P(s))$. The ODE is equipped with initial conditions $V(0)$ and $P(0)$. For simplicity, we set $\phi_V(s) = V(0)$ and $\phi_P(s) = P(0)$.

The j initial conditions for each $A_i(0)$ define j constraints on $\phi_G(s)$. There are many history function that satisfy these constraints and the ODE reduction of the DDE defines the same solution for each such history function. We show how to construct one such history function $\phi_G \in L^1((-\infty, 0], \mathbb{R}, \mu)$. Let the ODE system have initial conditions

$$\alpha_i = A_i(0) \quad \text{for } i = 1, 2, \dots, j \quad \text{and} \quad \alpha_i \in \mathbb{R},$$

and chose a sequence of points

$$0 < x_1 < \dots < x_j < \infty.$$

Now, we make the following ansatz for $\phi_G(s)$

$$\phi_G(s) = \sum_{n=1}^j b_n \delta(s + x_n), \quad (33)$$

where $\delta(x)$ is the Dirac function. We will show that is possible to chose the $\{b_n\}_{n=1}^j$ such that

$$\int_0^\infty \frac{a_2}{k_{tr}} g_{ktr}^i(\sigma) \exp \left[- \int_{-\sigma}^0 \hat{d}_g + \eta(U(s)) + \psi_G(U(s)) ds \right] \phi(-\sigma) d\sigma = \alpha_i. \quad (34)$$

However, the histories $\phi_V(s)$, $\phi_P(s)$ and $\phi_G(s)$ appear in the integral term

$$I = \int_{-\sigma}^0 \hat{d}_g + \eta(U(s)) + \psi_G(U(s)) ds,$$

so some care is needed. We have already set $\phi_V(s) = V(0)$ so $\eta(U(s))$ is defined on $(-\infty, 0]$, so we need only consider

$$\psi_G(U(s)) = \frac{k_p P(0)}{1 + \phi_G(s)} \quad \text{for } s < 0$$

with $\phi_P(s) = P(0)$. Inserting equation (33) for $\phi_G(s)$ gives

$$\psi_G(U(s)) = \frac{k_p P(0)}{1 + \sum_{n=1}^j b_n \delta(s + x_n)} = \begin{cases} k_p P(0) & \text{if } s \notin \{-x_i\}_{i=1}^j \\ 0 & \text{if } s \in \{-x_i\}_{i=1}^j. \end{cases}$$

Since ψ_G only appears in a Lebesgue integral and differs from $k_p P(0)$ on a set of measure 0, the following holds

$$\int_{-\sigma}^0 \hat{d}_g + \eta(U(s)) + \psi_G(U(s)) ds = \int_{-\sigma}^0 \hat{d}_g + \eta(U(s)) + k_p P(0) ds.$$

Therefore, finding $\{b_n\}_{n=1}^j$ such that equation (34) holds is equivalent to finding $\{b_n\}_{n=1}^j$ such that

$$\int_0^\infty \frac{a_2}{k_{tr}} g_{ktr}^i(\sigma) \exp \left[- \int_{-\sigma}^0 \hat{d}_g + \eta(U(s)) + k_p P(0) ds \right] \phi_G(-\sigma) d\sigma = \alpha_i. \quad (35)$$

Using the ansatz for ϕ_G in equation (35) gives the following system of equations for $i = 1, 2, \dots, j$

$$\alpha_i = \sum_{n=1}^j b_n \frac{a_2}{k_{tr}} g_{ktr}^i(x_n) \exp \left[- \int_{-x_n}^0 \hat{d}_g + \eta(U(s)) + k_p P(0) ds \right]. \quad (36)$$

To simplify notation, set

$$\mu_n = \int_{-x_n}^0 \hat{d}_g + \eta(U(s)) + k_p P(0) ds$$

and note μ_n is independent of the unknowns $\{b_n\}_{n=1}^j$.

Equation (36) defines a linear system of equations for the unknowns $\{b_n\}_{n=1}^j$. Consequently, there exists a unique solution to (36) if the matrix

$$A = \begin{bmatrix} \frac{a_2}{k_{tr}} g_{ktr}^1(-x_1) \exp[-\mu_1] & \cdots & \frac{a_2}{k_{tr}} g_{ktr}^1(-x_j) \exp[-\mu_j] \\ \frac{a_2}{k_{tr}} g_{ktr}^2(-x_1) \exp[-\mu_1] & \cdots & \frac{a_2}{k_{tr}} g_{ktr}^2(-x_j) \exp[-\mu_j] \\ \vdots & \ddots & \vdots \\ \frac{a_2}{k_{tr}} g_{ktr}^j(-x_1) \exp[-\mu_1] & \cdots & \frac{a_2}{k_{tr}} g_{ktr}^j(-x_j) \exp[-\mu_j] \end{bmatrix}$$

is invertible. To show this matrix is invertible, we will show that $\det(A) \neq 0$. Using the definition of $g_{k_{tr}}^j(x_i)$, the m -th column has a common factor of

$$\frac{a_2}{k_{tr}} e^{-k_{tr} x_m} \exp[-\mu_m] > 0$$

while, the n -th row has a common factor of $k_{tr}^n / (n-1)! > 0$ for $n, m = 1, 2, \dots, j$. Thus

$$\det(A) = \left[\prod_{n,m=1}^j \frac{a_2}{k_{tr}} e^{-k_{tr} x_m} \exp[-\mu_m] \frac{k_{tr}^n}{(n-1)!} \right] \det(V),$$

where

$$V = \begin{bmatrix} 1 & 1 & \cdots & 1 \\ x_1 & x_2 & \cdots & x_j \\ \vdots & \vdots & \ddots & \vdots \\ x_1^{j-1} & x_2^{j-1} & \cdots & x_j^{j-1} \end{bmatrix}$$

Since V is a Vandermonde Matrix and the $\{x_i\}_{i=1}^j$ are distinct, $\det(V) \neq 0$. Consequently, $\det(A) \neq 0$ so A is invertible and we can uniquely determine the $\{b_n\}_{n=1}^j$. $\square$

The equivalence between ODEs and gamma distributed DDEs has been used extensively since Vogel [1961]. Some authors have shown how to convert ODE transit compartment models to distributed DDE for specific initial conditions [Câmara De Souza et al., 2018; Cooke and Grossman, 1982]. However, to the author's knowledge this is the first proof of direct equivalence between an ODE and a distributed DDE for arbitrary ODE initial conditions established by explicitly constructing a suitable history function.

4.2 Numerical Results

For the purpose of numerical simulation, the system of finite dimensional ODEs derived in Section 4.1 is much more tractable than the distributed DDE. Numerically solving the distributed DDE requires the development and implementation of a numerical differential equation solver capable of accurately computing the semi-infinite convolution integral, while there are numerous existing methods for solving systems of ODEs. To solve the DDE given in equation (1), we simulate the equivalent ODE in equation (27) and calculate $N(t)$ as shown in Appendix B to illustrate the analytical results of Section 3.

For simplicity, we only present the dynamics of $Q(t)$, as these dynamics are representative of the full model's behaviour. The parameters used in these simulations are given in Table 1.

The smallest detectable tumour size has been estimated to be roughly $2^{30} \approx 1 \times 10^9$ cells [Carlson, 2003; Schwartz, 1961]. As viral oncology has only been approved for advanced melanoma, we consider tumours with approximately 10^{10} cells. (This corresponds to viral treatment starting 4 tumour doublings after diagnosis.) To ensure that our numerical computations involve numbers of similar magnitude, we measure the number of tumour cells in units of 10^{10} cells. Given the homeostatic approximation of leukocytes ($\approx 6 \times 10^9$ cells/L) and roughly 7 litres of blood, we measure the phagocyte concentration in identical units, namely 10^{10} cells.

To illustrate the difference between distributed and discrete delays in the cell cycle duration, we simulate equation (27) without viral therapy for $j = 6$ and the discrete delay case in Figure 2 a). In Figure 2 b), we show the discrete case and the gamma distributed case when $j = 50$. These simulations show that the discrete delay case has a larger basin of attraction than the distributed delay case. This is unsurprising, since for both $j = 6$ and $j = 50$, the result of Corollary 3.4 holds, so all parameter regimes leading to stability of the CFE for the gamma distributed DDE also lead to stability of the CFE in the discrete delay

Parameter	Value	Biological Interpretation (Unit)	Reference
a_1	0.9	Quiescent to interphase rate (1/day)	Crivelli et al. [2012]
d_1	1×10^{-5}	Quiescent death rate (1/day)	Crivelli et al. [2012]
a_2	0.7	Interphase to active phase rate (1/day)	Crivelli et al. [2012]
d_2	0.19	Interphase death rate (1/day)	Crivelli et al. [2012]
d_3	0.19	Active phase death rate (1/day)	Crivelli et al. [2012]
$\hat{d}_g$	0.167	Active phase death rate (1/day)	Calculated from equation (26)
κ	1.15	Virion contact rate (1/day)	Crivelli et al. [2012]
$\eta_{1/2}$	$V(0)/10$	Virion half effect concentration (virions)	See caption
δ	1.119	Lysis rate (1/day)	Crivelli et al. [2012]
α	1.65	Lytic virion release rate (virions/cell)	Crivelli et al. [2012]
ω	0.75	Virion death rate (1/day)	Crivelli et al. [2012]
k_{cp}	6.63	Maximal phagocyte production rate (10^{10} cells/day)	Schirm et al. [2016]
$C_{1/2}$	0.87743	Phagocyte production half effect (ng/mL/day)	Liu et al. [2007]
$\Psi_{1/2}$	7	Cytokine production half effect (10^{10} cells/day)	See caption
γ_p	1	Phagocyte death rate (1/day)	Liu et al. [2007]
C_{prod}^*	0.014161	Homeostatic cytokine production rate (ng/mL/day)	Craig et al. [2016]
C_{prod}^{max}	1.4161	Maximal cytokine production rate (ng/mL/day)	See caption
k_{elim}	0.16139	Cytokine elimination rate (1/day)	Craig et al. [2016]
k_p	0.065	Phagocyte-tumour cell contact rate (1/day)	Liu et al. [2007]
$k_{q,s}$	1.75	Phagocyte cell digestion constant	See caption
τ	2.13285	Expected cell cycle duration (day)	Crivelli et al. [2012]

Table 1: The parameters used to simulate equation (27) in Figure 3. $C_{1/2}$ was calculated from the homeostatic phagocyte production rate and k_p was calculated from the mass-action tumour-immune interaction from Liu et al. [2007]. C_{prod}^{max} was calculated from G-CSF response to infection [Pauksen et al., 1994]. $\eta_{1/2}$ was chosen to ensure a high initial infectivity of viral therapy while $k_{q,s}$ and $\Psi_{1/2}$ were selected to give physiologically realistic simulations.

case. Biologically, this corresponds to increased cell cycle duration heterogeneity leading to more robust tumours.

In Figure 2, we also show the impact of including tumour-immune interaction by comparing our model with that of Crivelli et al. [2012]. We compare the results of our simulation with tumour-immune interaction ($k_p = 0.065$) with the Crivelli model ($k_p = 0$) as written in Appendix A. This simulation underlies the importance of tumour-immune interaction in determining disease progression.

In Appendix A, we show that the gamma distribution converges to the degenerate distribution as j grows infinitely large, with $\tau > 0$ held constant. The case $j = 1$ corresponds to an exponential distribution of cell cycle durations. In what follows, we assume that the distribution of cell cycle durations is neither exponential nor degenerate, so $1 < j < \infty$. In the numerical simulations that follow, we illustrate a representative case of our results with $j = 6$.

In Figure 3, we simulate the finite dimensional representation of the distributed DDE (1) for different levels of immune recruitment, k_{cp} , during viral therapy. Figure 3 shows that changing k_{cp} changes the long-term success or failure of viral treatment. Sufficiently large values of k_{cp} induce long-lasting remission while smaller values of k_{cp} lead to eventual tumour progression after oncolytic virus treatment.

Figure 4 shows the impact of parameter variability on stability of the CFE. Figure 4 (a) shows that increased immune interaction (k_p) can counteract fast transit between quiescence and mitosis (a_1 and a_2 respectively) to ensure stability of the CFE. Moreover, sufficiently slow entrance into the active phase of the cell cycle (small a_2) also stabilises the CFE. Figure 4 (b) shows that immune recruitment (k_{cp}) must grow infinitely

Figure 2: A comparison of simulation results for various distributions with $k_{cp} = 2.65$. Figure (a) shows the simulation of equation (1) with a gamma distribution for $j = 6$ in blue, a discrete delay in red and the Crivelli model (equation (37)) in black. Figure (b) shows the simulation of equation (1) with a gamma distribution for $j = 50$ in blue, a discrete delay in red and the Crivelli model (equation (37)) in black.

Figure 3: Simulated viral therapy with limited and sufficient immune recruitment. The parameters used in sufficient immune recruitment are given in Table 1. Limited immune recruitment occurs with $k_{cp} = 1.63$ and other parameters as given in Table 1.

large to account for less efficient immune-tumour interaction (k_p), while a large death rate during the cell cycle ($\hat{d}_g$) can ensure stability of the CFE regardless of immune involvement. These investigations confirm the impact of immune recruitment and clearance of tumour cells. This result indicates that increasing immune involvement is important in developing therapeutic strategies.

Finally, Figure 5 shows the relationship between the nonzero equilibrium found in Theorem 3.5 and the parameter k_p . The diagram indicates that the CFE gains stability through a transcritical bifurcation as k_p

Figure 4: Stability regions for the cancer free equilibrium for various parameter combinations. Figure (a) shows the relationship between the stability of the CFE and the parameters k_p , a_1 and a_2 . Figure (b) shows the relationship between stability of the CFE and the parameters k_{cp} , k_p and $\hat{d}_g$.

Figure 5: The bifurcation diagram showing a transcritical bifurcation. Figure (a) shows the transcritical bifurcation as k_p increases past k_p^{crit} for the quiescent population. The dashed lines represent unstable equilibria and the solid lines denote stable equilibria. Figure (b) the dependence of asymptotic behaviour on initial conditions. The quiescent initial populations used are shown in Figure (a) as crosses.

increases. For $k_p > k_p^{crit}$ and initial conditions straddling the unstable equilibrium, we see the dependence of asymptotic behaviour on initial conditions. A similar relationship exists between the stability of the CFE and k_{cp} . Biologically, Figure 5 (b) shows that the same immune system can control small tumours while large established tumours grow unboundedly.

5 Discussion

Malignant tumours are comprised of an extremely heterogeneous population of malignant cells. Oncolytic viruses combat this heterogeneity by exploiting two common characteristics of malignant cells: weakened antiviral immunity and explosive growth rates. Once an oncolytic virus has infiltrated a tumour, lysis of infected cells and immune recruitment combine to eliminate the tumour. Past models of tumour growth and viral oncology have used discrete DDEs to model the cell cycle duration and infection of susceptible cells. However, discrete DDEs enforce a uniform and constant tumour cell cycle time and do not incorporate any aspect of the inherent heterogeneity of malignant cells inside the tumour microenvironment.

In this work, we produced a mathematical model of tumour cell growth that incorporates the heterogeneity of tumour reproduction speed by modelling cell cycle duration as a random variable following a PDF $K(t)$. This framework is a novel representation of tumour growth and is more physiologically realistic than the discrete delay case. Specifically, variation in tumour cell cycle duration can be seen as a measure of tumour cell heterogeneity. Using linear stability analysis, we established the relationship between the expected number of cells surviving the cell cycle and tumour remission. As we assumed a constant death rate throughout the cell cycle, the expected number of cells surviving the cell cycle is directly related to the distribution of cell cycle durations. The distribution of cell cycle durations and disease progression are explicitly linked in our stability threshold. The stability threshold determines the minimal anti-tumour immune response that ensures that nascent tumours do not persist. This result shows that increasing immune involvement can stabilise the tumour free state regardless of the cancer growth rate.

Our results indicate that lysis of infected cells and increased immune recruitment act synergistically to eliminate tumour cells during viral therapy. Our simulations show that the combination of viral therapy and the resulting immune recruitment function by driving solutions across a separatrix into the basin of attraction of the tumour free equilibrium. If immune recruitment is insufficient to control tumour growth, we predict that viral therapy will drive initial tumour remission that is followed by disease recurrence. Moreover, our results show that viral therapy can act as the external force required to shrink tumours to a size manageable by the immune system, leading to long-term remission. These observations are consistent with clinical results and suggest that oncolytic viruses designed to maximise immune response may have clinical benefits.

Finally, our modelling techniques develop a novel mathematical treatment of tumour cell growth by using a distributed DDE. The distributed DDE considered in this work incorporates the discrete delay case studied by Crivelli et al. [2012] and others for a suitable choice of $K(t)$ and k_p . In the specific case of a gamma distribution, we derive a novel linear chain technique that incorporates cellular loss throughout the cell cycle. Using this technique, we reduce the infinite dimensional distributed DDE to an equivalent finite dimensional ODE. Our derivation of the equivalent ODE formulation is easily generalisable to physiological processes with exponential growth or decay. The reduction of the distributed DDE to an ODE offers a method whereby models using discrete DDEs can include more physiologically realistic distributed delays without losing the ability to easily simulate the model.

Our modelling framework has certain limitations. The mathematical model greatly simplifies immune recruitment and tumour-immune interactions in favour of an analytically tractable model. The interactions between the legion of cytokines and immune cell types in the tumour micro-environment are not considered in this work, nor have we studied the effect of immune system selection of cancer cells.

This modelling work raises the interesting question of which distribution best models tumour cell cycle durations. Most existing models either use the discrete or gamma distribution to exploit the existing numerical methods to simulate these models. Without data, it is difficult to determine which distribution most accurately models tumour cell cycle durations. Nevertheless, our analytic results are valid for any distribution describing tumour cell cycle durations. In summary, our model incorporates an aspect of tumour cell heterogeneity, makes predictions that are consistent with clinical observations and indicates

future avenues of oncolytic virus development.

Acknowledgements

TC would like to thank the Natural Sciences and Engineering Research Council of Canada (NSERC) for funding through the PGS-D program and the Alberta Government for funding through the Sir James Lougheed award of distinction. ARH is grateful to NSERC, Canada for funding through the Discovery Grant program. Both authors thank Morgan Craig for many helpful discussions.

References

- Bartlett, D. L., Liu, Z., Sathaiah, M., Ravindranathan, R., Guo, Z., He, Y., and Guo, Z. S. (2013). Oncolytic viruses as therapeutic cancer vaccines. *Mol. Cancer*, 12(1):103.
- Bell, J. and McFadden, G. (2014). Viruses for tumor therapy. *Cell Host Microbe*, 15(3):260–265.
- Bhatia, A. and Kumar, Y. (2011). Cancer-immune equilibrium: Questions unanswered. *Cancer Microenviron.*, 4(2):209–217.
- Bommareddy, P. K., Patel, A., Hossain, S., and Kaufman, H. L. (2017). Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. *Am. J. Clin. Dermatol.*, 18(1):1–15.
- Bourgeois-Daigneault, M. C., Roy, D. G., Falls, T., Twumasi-Boateng, K., St-Germain, L. E., Marguerie, M., Garcia, V., Selman, M., Jennings, V. A., Pettigrew, J., Amos, S., Diallo, J. S., Nelson, B., and Bell, J. C. (2016). Oncolytic vesicular stomatitis virus expressing interferon-gamma has enhanced therapeutic activity. *Mol. Ther. - Oncolytics*, 3:16001.
- Breitbach, C. J., Lichty, B. D., and Bell, J. C. (2016). Oncolytic viruses: Therapeutics with an identity crisis. *EBioMedicine*, 9:31–36.
- Burns, F. J. and Tannock, J. F. (1970). On the existence of a G₀-phase in the cell cycle. *Cell Tissue Kinet.*, 3(4):321–334.
- Câmara De Souza, D., Craig, M., Cassidy, T., Li, J., Nekka, F., Bélair, J., and Humphries, A. R. (2018). Transit and lifespan in neutrophil production: implications for drug intervention. *J. Pharmacokinet. Pharmacodyn.*, 45(1):59–77.
- Campbell, S. A. and Jessop, R. (2009). Approximating the Stability Region for a Differential Equation with a Distributed Delay. *Math. Model. Nat. Phenom.*, 4(2):1–27.
- Carlson, J. A. (2003). Tumor doubling time of cutaneous melanoma and its metastasis. *Am. J. Dermatopathol.*, 25(4):291–299.
- Cassady, K., Haworth, K., Jackson, J., Markert, J., and Cripe, T. (2016). To infection and beyond: The multi-pronged anti-cancer mechanisms of oncolytic viruses. *Viruses*, 8(2):43.
- Chiocca, E. A. and Rabkin, S. D. (2015). Oncolytic viruses and their application to cancer immunotherapy. *Cancer Immunol. Res.*, 2(4):295–300.
- Cooke, K. L. and Grossman, Z. (1982). Discrete delay, distributed delay and stability switches. *J. Math. Anal. Appl.*, 86(2):592–627.
- Craig, M., Humphries, A. R., and Mackey, M. C. (2016). A mathematical model of granulopoiesis incorporating the negative feedback dynamics and kinetics of G-CSF/neutrophil binding and internalization. *Bull. Math. Biol.*, 78(12):2304–2357.
- Crivelli, J. J., Földes, J., Kim, P. S., and Wares, J. R. (2012). A mathematical model for cell cycle-specific cancer virotherapy. *J. Biol. Dyn.*, 6(sup1):104–120.
- Dawson, A. and Hillen, T. (2006). Derivation of the tumour control probability (TCP) from a cell cycle model. *Comput. Math. Methods Med.*, 7(2-3):121–141.
- Diekmann, O., Gyllenberg, M., and Metz, J. A. J. (2017). Finite dimensional state representation of linear and nonlinear delay systems. *J. Dyn. Differ. Equations*.
- Dominguez-Brauer, C., Thu, K. L., Mason, J. M., Blaser, H., Bray, M. R., and Mak, T. W. (2015). Targeting mitosis in cancer: emerging strategies. *Mol. Cell*, 60(4):524–536.

- Fukuhara, H., Ino, Y., and Todo, T. (2016). Oncolytic virus therapy: A new era of cancer treatment at dawn. *Cancer Sci.*, 107(10):1373–1379.
- Grivennikov, S. I. and Karin, M. (2011). Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. *Ann. Rheum. Dis.*, 70(Suppl 1):i104–i108.
- Hale, J. K. and Verduyn Lunel, S. M. (1993). *Introduction to Functional Differential Equations*, volume 99 of *Applied Mathematical Sciences*. Springer New York, New York, NY.
- Hallam, S., Escorcio-Correia, M., Soper, R., and Schultheiss, A. (2009). Activated macrophages in the tumour microenvironment - dancing to the tune of TLR and NF- κ B. *J. Pathol.*, 219(2):143–152.
- Hillen, T., Enderling, H., and Hahnfeldt, P. (2013). The tumor growth paradox and immune system-mediated selection for cancer stem cells. *Bull. Math. Biol.*, 75(1):161–184.
- Hino, Y., Murakami, S., and Naito, T. (1991). *Functional Differential Equations with Infinite Delay*, volume 1473 of *Lecture Notes in Mathematics*. Springer Berlin Heidelberg, Berlin, Heidelberg.
- Hoos, A., Britten, C. M., Huber, C., and O'Donnell-Tormey, J. (2011). A methodological framework to enhance the clinical success of cancer immunotherapy. *Nat. Biotechnol.*, 29(10):867–870.
- Hu, S., Dunlavey, M., Guzy, S., and Teuscher, N. (2018). A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies. *J. Pharmacokinet. Pharmacodyn.*, 45(2):1–24.
- Idema, S., Dirven, C. M. F., van Beusechem, V., Carette, J., Planqué, R., Noske, D. P., Lamfers, M. L. M., and Vandertop, W. P. (2010). Objective determination of the oncolytic potency of conditionally-replicating adenoviruses using mathematical modeling. *J. Gene Med.*, 12(7):564–571.
- Imran, M. and Smith, H. L. (2007). The dynamics of bacterial infection, innate immune response, and antibiotic treatment. *Discret. Contin. Dyn. Syst. B*, 8(1):127–143.
- Kim, P. S., Crivelli, J. J., Choi, I., Yun, C., and Wares, J. R. (2015). Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics. *Math. Biosciences Eng.*, 12(4):841–58.
- Kirschner, D. and Panetta, J. C. (1998). Modeling immunotherapy of the tumor - immune interaction. *J. Math. Biol.*, 37(3):235–252.
- Krzyzanski, W., Wiczling, P., Lowe, P., Pigeolet, E., Fink, M., Berghout, A., and Balser, S. (2010). Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations. *J. Clin. Pharmacol.*, 50(S9):101S–112S.
- Lawler, S. E. and Chiocca, E. A. (2015). Oncolytic virus-mediated immunotherapy: A combinatorial approach for cancer treatment. *J. Clin. Oncol.*, 33(25):2812–2814.
- Lichty, B. D., Breitbach, C. J., Stojdl, D. F., and Bell, J. C. (2014). Going viral with cancer immunotherapy. *Nat. Rev. Cancer*, 14(8):559–567.
- Liu, W., Hillen, T., and Freedman, H. I. (2007). A mathematical model for M-phase specific chemotherapy including the G0-phase and immunoresponse. *Math. Biosci. Eng.*, 4(2):239–59.
- MacNamara, C. and Eftimie, R. (2015). Memory versus effector immune responses in oncolytic virotherapies. *J. Theor. Biol.*, 377:1–9.
- Mahasa, K. J., Eladdadi, A., de Pillis, L., and Ouifki, R. (2017). Oncolytic potency and reduced virus tumor- specificity in oncolytic virotherapy. A mathematical modelling approach. *PLoS One*, 12(9):1–25.
- Malinzi, J., Eladdadi, A., and Sibanda, P. (2017). Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment. *J. Biol. Dyn.*, 11(1):244–274.
- Matheson, C. J., Backos, D. S., and Reigan, P. (2016). Targeting WEE1 Kinase in Cancer. *Trends Pharmacol. Sci.*, 37(10):872–881.
- Mittal, D., Gubin, M. M., Schreiber, R. D., and Smyth, M. J. (2014). New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. *Curr. Opin. Immunol.*, 27:16–25.
- Mosser, D. M. (2003). The many faces of macrophage activation. *J. Leukoc. Biol.*, 73(2):209–212.

- Pauksen, K., Elfman, L., Ulfgren, A., and Venge, P. (1994). Serum levels of granulocyte-colony stimulating factor (G-CSF) in bacterial and viral infections, and in atypical pneumonia. *Br J Haematol*, 88(2):256–260.
- Piscitelli, S., Reiss, W., Figg, W., and Petros, W. (1997). Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. *Clin. Pharmacokinet.*, 32(5):368–81.
- Rehman, H., Silk, A. W., Kane, M. P., and Kaufman, H. L. (2016). Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. *J. Immunother. Cancer*, 4(1):1–8.
- Santiago, D. N., Heidbuechel, J. P. W., Kandell, W. M., Walker, R., Djeu, J., Engeland, C. E., Abate-Daga, D., and Enderling, H. (2017). Fighting cancer with mathematics and viruses. *Viruses*, 9(9):1–26.
- Schirm, S., Ahnert, P., Wienhold, S., Mueller-Redetzky, H., Nouailles-Kursar, G., Loeffler, M., Witzenrath, M., and Scholz, M. (2016). A biomathematical model of pneumococcal lung infection and antibiotic treatment in mice. *PLoS One*, 11(5):1–22.
- Schwartz, M. (1961). A biomathematical approach to clinical tumor growth. *Cancer*, 14(6):1272–1294.
- Smith, H. (2011). *An Introduction to Delay Differential Equations with Applications to the Life Sciences*. Springer, New York, New York, USA.
- Swann, J. B. and Smyth, M. J. (2007). Immune surveillance of tumors. *J. Clin. Invest.*, 117(5):1137–1146.
- Villasana, M. and Radunskaya, A. (2003). A delay differential equation model for tumor growth. *J. Math. Biol.*, 47(3):270–294.
- Visconti, R., Della Monica, R., and Grieco, D. (2016). Cell cycle checkpoint in cancer: A therapeutically targetable double-edged sword. *J. Exp. Clin. Cancer Res.*, 35(1):153.
- Vogel, T. (1961). Systèmes Déferlants, Systèmes Héréditaires, Systèmes Dynamiques. In *Proc. Int. Symp. Nonlinear Vib.*, pages 123–130, Kiev. Academy of Sciences USSR.
- Walker, R. and Enderling, H. (2016). From concept to clinic: Mathematically informed immunotherapy. *Curr. Probl. Cancer*, 40(1):68–83.
- Wodarz, D. (2016). Computational modeling approaches to the dynamics of oncolytic viruses. *Wiley Interdiscip. Rev. Syst. Biol. Med.*, 8(3):242–252.

Appendix A Reduction to the Crivelli Model and the Discrete Delay Case

We show that the Crivelli model [Crivelli et al., 2012] is a special case of the general distributed DDE model (1) developed in Section 2 without immune recruitment. We do this two ways, first by showing that the discrete DDE model corresponds to the distributed DDE model with a degenerate distribution. Then alternatively by showing that the discrete DDE model can be recovered from the distributed DDE model in a suitable limit when $K(t)$ is taken to be a Gamma distribution.

Crivelli et al. [2012] do not consider tumour-immune involvement, so we take $k_p = 0$ in (1). Then, the immune recruitment has no impact on the tumour model, so we drop the differential equations for $P(t)$ and $C(t)$. Crivelli et al. [2012] use a discrete DDE to model the cell cycle duration. The simplest way to recover a discrete DDE from a distributed DDE is to let $K(t) = \delta(t - \tau)$. Then, equation (7) gives $d_\delta = d_3$. Thus the model (1) becomes

$$\left. \begin{aligned} \frac{d}{dt}Q(t) &= 2 \exp[-d_3\tau] a_2 G_1(t - \tau) \delta_\tau(t - \sigma) - a_1 Q(t) - d_1 Q(t) \\ \frac{d}{dt}G_1(t) &= a_1 Q(t) - a_2 G_1(t) - d_2 G_1(t) - \eta(U(t)) G_1(t) \\ \frac{d}{dt}I(t) &= -\delta I(t) + \eta(U(t)) [G_1(t) + \int_0^\tau G_1(\sigma) \exp[-d_3\sigma] d\sigma] \\ \frac{d}{dt}V(t) &= \alpha I(t) - \omega V(t) - \eta(U(t)) [G_1(t) + \int_0^\tau a_2 G_1(\sigma) \exp[-d_3\sigma] d\sigma] \end{aligned} \right\} \quad (37)$$

Finally, evaluating equation (2) with $K(t) = \delta(t - \tau)$ gives

$$\begin{aligned} N(t) &= \int_0^\infty a_2 G_1(t - \xi) \exp \left[- \int_{t-\xi}^t \hat{d}_K + \psi_G(U(x)) + \eta(U(x)) dx \right] \left(1 - \int_0^\xi \delta(\sigma - \tau) d\sigma \right) d\xi \\ &= \int_0^\tau a_2 G_1(t - \xi) \exp \left[- \int_{t-\xi}^t \hat{d}_K + \psi_G(U(x)) + \eta(U(x)) dx \right] d\xi, \end{aligned}$$

and taking $\eta(U(t))$ to be the non-differentiable contact rate

$$\eta(U(t)) = \kappa \frac{V(t)}{V(t) + I(t) + G_1(t) + N(t) + Q(t)},$$

returns the mathematical model in Crivelli et al. [2012]. To illustrate that their results are a special case of ours, we use Theorem 3.3 to determine the stability of the CFE for the Crivelli model. With $k_p = 0$ and $K(t) = \delta(t - \tau)$, it is simple to calculate that $\Psi_{G_1} = 0$ and

$$\mathcal{L}[\delta(t - \tau)](d_3) = e^{-d_3\tau}.$$

Then the stability condition (22) becomes

$$2a_1a_2e^{-d_3\tau} - (a_1 + d_1)(a_2 + d_2) < 0, \quad (38)$$

which is exactly the same as found by Crivelli et al. [2012].

We have shown that discrete DDEs can be modelled as degenerate distributed DDEs. Next, we show a distinct method of reducing the general distributed DDE to a discrete DDE by considering a gamma distributed DDE, i.e. $K(t) = g_{k_{tr}}^j(t)$, in the limit as $j \rightarrow \infty$. We parameterise the gamma distribution by choosing $j \in \mathbb{N}$ and setting $a_j = \tau/j$. Then, for each integer j , the expected duration of the cell cycle is τ . Moreover, the standard deviation is given by $s_j^2 = \tau^2/j$ with

$$\lim_{j \rightarrow \infty} s_j^2 = 0.$$

Heuristically, as j increases, $g_a^j(t)$ becomes increasingly concentrated about the expected value, τ . Formally, the characteristic function of the gamma distribution converges in distribution to the characteristic function of the $\delta(t - \tau)$ distribution with

$$\int_0^\infty y(t - \sigma) g_{j/\tau}^j(\sigma) d\sigma \rightarrow y(t - \tau) \quad \text{as } j \rightarrow \infty$$

for any test function $y(t)$. From equation (26), $\hat{d}_g$ is dependent on the parameter j via

$$\hat{d}_g^j = \frac{j}{\tau} \left[(e^{d_3\tau})^{1/j+1} - 1 \right].$$

To compute the limit of $\hat{d}_g^j$ as $j \rightarrow \infty$, we first note that

$$\lim_{n \rightarrow \infty} n(a^{1/n} - 1) = \lim_{n \rightarrow \infty} \frac{a^{1/n} - 1}{1/n} = \frac{d}{dt} a^t \Big|_{t=0} = \ln(a). \quad (39)$$

Therefore,

$$\lim_{j \rightarrow \infty} \hat{d}_g^j = \lim_{j \rightarrow \infty} \frac{j}{\tau} \left[(e^{d_3\tau})^{1/j+1} - 1 \right] = \frac{1}{\tau} \ln(e^{d_3\tau}) = d_3,$$

so $\hat{d}_g^j$ converges to the death rate of the discrete DDE as $j \rightarrow \infty$.

Finally, we compute the linearisation matrix for the linearised DDE (17) with $K(t) = g_a^j(t)$:

$$\mathbb{A} + \mathcal{L}[\Gamma](\lambda + \hat{d}_g^j + k_p P^*) \mathbb{B} = \begin{bmatrix} -(a_1 + d_1 + k_p P^*) & 2a_2 \frac{a^j}{(a + \lambda + \hat{d}_g^j + k_p P^*)^j} & 0 & 0 & 0 & 0 \\ a_1 & -(a_2 + d_2 + k_p P^*) & 0 & 0 & 0 & 0 \\ 0 & 0 & -\gamma & 0 & 0 & 0 \\ 0 & 0 & \alpha & -\omega & 0 & 0 \\ \xi k_p P^* & \xi k_p P^* & \xi \delta & 0 & \frac{-k_{elim}}{(C_{1/2} + C^*)^2} & 0 \\ 0 & 0 & 0 & 0 & \frac{k_{cp} C_{1/2}}{(C_{1/2} + C^*)^2} & -\gamma_P \end{bmatrix}$$

and the corresponding characteristic function, once again using equation (19),

$$q(\lambda) = \rho(\lambda) \left[2a_1a_2 \frac{a^j}{(a + \lambda + \hat{d}_g^j + k_p P^*)^j} - (a_1 + d_1 + k_p P^* + \lambda)(a_2 + d_2 + k_p P^* + \lambda) \right].$$

Using Theorem 3.3, the condition for stability of the CFE is

$$2a_1a_2 \frac{a^j}{(a + \hat{d}_g^j + k_p P^*)^j} - (a_1 + d_1 + k_p P^*)(a_2 + d_2 + k_p P^*) < 0. \quad (40)$$

Using $a = j/\tau$, we rearrange this condition to find a cell cycle duration, τ_j , that ensures local stability of the CFE

$$\tau_j > \frac{j}{\hat{d}_g^j + k_p P^*} \left[\left(\frac{2a_1a_2}{(a_1 + d_1 + k_p P^*)(a_2 + d_2 + k_p P^*)} \right)^{1/j} - 1 \right].$$

Then, the minimal cell cycle duration for stability, τ_j^* , is given by

$$\tau_j^* = \frac{j}{\hat{d}_g^j + k_p P^*} \left[\left(\frac{2a_1 a_2}{(a_1 + d_1 + k_p P^*)(a_2 + d_2 + k_p P^*)} \right)^{1/j} - 1 \right]$$

and is dependent on the parameter j . Once again, using equation (39), we see that

$$\lim_{j \rightarrow \infty} \tau_j^* = \lim_{j \rightarrow \infty} \frac{j}{\hat{d}_g^j + k_p P^*} \left[\left(\frac{2a_1 a_2}{(a_1 + d_1 + k_p P^*)(a_2 + d_2 + k_p P^*)} \right)^{1/j} - 1 \right] = \frac{1}{\hat{d}_3 + k_p P^*} \left[\ln \left(\frac{2a_1 a_2}{(a_1 + d_1 + k_p P^*)(a_2 + d_2 + k_p P^*)} \right) \right].$$

Thus the critical cell cycle duration when $K(t) = g_a^j(t)$ converges to the critical cell cycle duration time in discrete delay case. Moreover, when $k_p = 0$, τ_j^* converges to the critical delay time found by Crivelli et al. [2012].

Consequently, the discrete DDE model considered by Crivelli et al. [2012] can be considered a degenerate case of the distributed DDE or as a limit of a gamma type distributions.

Appendix B Number of Cells in the Cell Cycle

Here, we detail the calculation of the number of cells in the active portion of the cell cycle at time t . Fix $\xi > 0$, so the number of cells entering the active portion of the cell cycle at time $t - \xi$ is $a_2 G_1(t - \xi)$.

Then, at time t , the probability that a cell that entered the active portion of the cell cycle at time $t - \xi$ has not completed the cell cycle is

$$\int_{\xi}^{\infty} K(\sigma) d\sigma = 1 - \int_0^{\xi} K(\sigma) d\sigma.$$

Of the cells that have not exited the active portion of the cell cycle, the fraction that have not died by time t is

$$a_2 G_1(t - \xi) \exp \left[- \int_{t-\xi}^t \hat{d}_K + \psi_G(U(x)) + \eta(U(x)) dx \right].$$

Integrating over all previous times ξ gives the total number of cells remaining in the cell cycle. Consequently, the number of cells in the cell cycle at time t is

$$N(t) = \int_0^{\infty} a_2 G_1(t - \xi) \exp \left[- \int_{t-\xi}^t \hat{d}_K + \psi_G(U(x)) + \eta(U(x)) dx \right] \left(1 - \int_0^{\xi} K(\sigma) d\sigma \right) d\xi. \quad (41)$$

By making the change of variable $\nu = t - \xi$, we have the alternative form

$$N(t) = \int_{-\infty}^t a_2 G_1(\nu) \exp \left[- \int_{\nu}^t \hat{d}_K + \psi_G(U(x)) + \eta(U(x)) dx \right] \left(1 - \int_0^{t-\nu} K(\sigma) d\sigma \right) d\nu. \quad (42)$$

Equation (42) is difficult to evaluate numerically. However, differentiating $N(t)$ by using the Lebeniz and product rules, we find the distributed DDE for $N(t)$

$$\begin{aligned} \frac{d}{dt} N(t) &= a_2 G_1(t) - \left[\hat{d}_K + \psi_G(U(t)) + \eta(U(t)) \right] N(t) \\ &\quad - \int_0^{\infty} a_2 G_1(t - \xi) \exp \left[- \int_{t-\xi}^t \hat{d}_K + \psi_G(U(x)) + \eta(U(x)) dx \right] K(\xi) d\xi \end{aligned} \quad (43)$$

which can be solved numerically. As we have shown in Proposition 4.1, we can replace the distributed DDE (43) with the solution of the transit compartment ODE defined in equation (29) when $K(\sigma) = g_a^j(\sigma)$. Therefore, in our simulations of equation (27), we calculate $N(t)$ by solving

$$\frac{d}{dt} N(t) = a_2 G_1(t) - \left[\hat{d}_K + \psi_G(U(t)) + \eta(U(t)) \right] N(t) - \frac{k_{tr}}{a_2} A_j(t), \quad (44)$$

subject to the initial condition from evaluating equation (41) at $t = 0$ by using the lower incomplete gamma function.